Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 1.13.11.52 - indoleamine 2,3-dioxygenase and Organism(s) Homo sapiens and UniProt Accession P14902

for references in articles please use BRENDA:EC1.13.11.52
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
A protohemoprotein. Requires ascorbic acid and methylene blue for activity. This enzyme has broader substrate specificity than EC 1.13.11.11, tryptophan 2,3-dioxygenase . It is induced in response to pathological conditions and host-defense mechanisms and its distribution in mammals is not confined to the liver . While the enzyme is more active with D-tryptophan than L-tryptophan, its only known function to date is in the metabolism of L-tryptophan [2,6]. Superoxide radicals can replace O2 as oxygen donor [4,7].
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
UNIPROT: P14902
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
Synonyms
indoleamine 2,3-dioxygenase, indoleamine-2,3-dioxygenase, tryptophan pyrrolase, tryptophan oxygenase, indoleamine 2,3 dioxygenase, indoleamine 2,3-dioxygenase-1, indolamine 2,3-dioxygenase, tryptophan dioxygenase, hido1, indoleamine-pyrrole 2,3-dioxygenase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
indoleamine 2,3-dioxygenase
-
indoleamine 2,3-dioxygenase 1
-
indoleamine 2,3-dioxygenase-1
-
INDOL1
indolamine 2,3-dioxygenase
indole 2,3-dioxygenase
-
-
indoleamine 2, 3-dioxygenase
-
-
indoleamine 2,3 dioxygenase
-
-
indoleamine 2,3-dioxygenase
indoleamine 2,3-dioxygenase 1
-
-
indoleamine 2,3-dioxygenase 2
indoleamine 2,3-dioxygenase-1
-
-
indoleamine 2,3-dioxygenase-2
indoleamine 2,3-dioxygenase-like protein
indoleamine-2,3-dioxygenase
-
-
L-tryptophan pyrrolase
-
-
-
-
oxygenase, tryptophan 2,3-di-
-
-
-
-
superoxygenase
-
-
-
-
TO
-
-
-
-
TRPO
-
-
-
-
Tryptamin 2,3-dioxygenase
-
-
-
-
tryptamine 2,3-dioxygenase
-
-
-
-
tryptophan 2,3-dioxygenase
-
-
tryptophan dioxygenase
-
-
tryptophan oxygenase
-
-
-
-
tryptophan peroxidase
-
-
-
-
tryptophan pyrrolase
-
-
-
-
tryptophanase
-
-
-
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
L-tryptophan + O2 = N-formyl-L-kynurenine
show the reaction diagram
L-tryptophan + O2 = N-formyl-L-kynurenine
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
redox reaction
-
-
-
-
oxidation
-
-
-
-
reduction
-
-
-
-
PATHWAY SOURCE
PATHWAYS
-
-, -, -, -, -
SYSTEMATIC NAME
IUBMB Comments
D-tryptophan:oxygen 2,3-oxidoreductase (decyclizing)
A protohemoprotein. Requires ascorbic acid and methylene blue for activity. This enzyme has broader substrate specificity than EC 1.13.11.11, tryptophan 2,3-dioxygenase [1]. It is induced in response to pathological conditions and host-defense mechanisms and its distribution in mammals is not confined to the liver [2]. While the enzyme is more active with D-tryptophan than L-tryptophan, its only known function to date is in the metabolism of L-tryptophan [2,6]. Superoxide radicals can replace O2 as oxygen donor [4,7].
CAS REGISTRY NUMBER
COMMENTARY hide
9014-51-1
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
1-methyl-D-tryptophan + O2
N-methyl-N-formyl-D-kynurenine
show the reaction diagram
-
-
-
?
1-methyl-L-tryptophan + O2
N-methyl-N-formyl-L-kynurenine
show the reaction diagram
5-fluoro-DL-tryptophan + O2
5-fluoro-N-formyl-DL-kynurenine
show the reaction diagram
-
-
-
?
5-fluoro-L-tryptophan + O2
5-fluoro-N-formyl-L-kynurenine
show the reaction diagram
-
-
-
?
5-hydroxy-L-tryptophan + O2
(2S)-4-(2-amino-5-hydroxyphenyl)-2-(formylamino)-4-oxobutanoic acid
show the reaction diagram
-
-
-
?
5-hydroxy-L-tryptophan + O2
5-hydroxy-N-formyl-L-kynurenine
show the reaction diagram
5-methoxy-DL-tryptophan + O2
5-methoxy-N-formyl-DL-kynurenine
show the reaction diagram
-
-
-
?
5-methoxy-L-tryptophan + O2
5-methoxy-N-formyl-L-kynurenine
show the reaction diagram
-
-
-
?
5-methyl-DL-tryptophan + O2
5-methyl-N-formyl-DL-kynurenine
show the reaction diagram
6-methyl-DL-tryptophan + O2
6-methyl-N-formyl-DL-kynurenine
show the reaction diagram
-
-
-
?
beta-[3-benzo(b)thienyl]-L-alanine + O2
?
show the reaction diagram
-
-
-
?
D-tryptophan + O2
N-formyl-D-kynurenine
show the reaction diagram
indole-3-propionic acid + O2
?
show the reaction diagram
altered kinetics for IPA (very long lag phase) as being consistent with a role for the ammonium group in stabilizing the ferric superoxide complex (via the radical pathway). The rate-limiting steps are different from the other substrates examined so that Compound II does not accumulate, but product formation is still possible, product formation ananlysis by LC-MS
-
-
?
L-Trp + O2
L-formylkynurenine
show the reaction diagram
induction by interferongamma
-
-
?
L-tryptophan + O2
N-formyl-L-kynurenine
show the reaction diagram
L-tryptophan + O2
N-formylkynurenine
show the reaction diagram
-
-
-
?
serotonin + O2
?
show the reaction diagram
-
-
-
?
tryptamine + O2
?
show the reaction diagram
-
-
-
?
1-benzofuran-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 22% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
1-benzothiophene-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 19% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
1-methyl-D-tryptophan + O2
N-methyl-N-formyl-D-kynurenine
show the reaction diagram
-
-
-
?
1-methyl-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 7% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
1-methyl-L-tryptophan + O2
?
show the reaction diagram
-
-
-
-
?
1-methyl-L-tryptophan + O2
N-methyl-N-formyl-L-kynurenine
show the reaction diagram
-
-
-
?
2-bromo-L-tryptophan + O2
?
show the reaction diagram
-
1 mM, 21% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
2-chloro-L-tryptophan + O2
?
show the reaction diagram
-
1 mM, 33% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
2-hydroxy-L-tryptophan + O2
?
show the reaction diagram
-
1 mM, 4% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
4-methyl-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 33% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
5-benzyloxy-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 1% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
5-bromo-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 36% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
5-fluoro-DL-tryptophan + O2
5-fluoro-N-formyl-DL-kynurenine
show the reaction diagram
-
-
-
?
5-fluoro-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 46% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
5-fluoro-tryptophan + O2
4-(2-amino-5-fluorophenyl)-2-(formylamino)-4-oxobutanoic acid
show the reaction diagram
-
-
-
?
5-fluoro-tryptophan + O2
?
show the reaction diagram
-
-
-
?
5-fluorotryptophan + O2
?
show the reaction diagram
-
-
-
-
?
5-hydroxy-L-tryptophan + O2
?
show the reaction diagram
5-hydroxy-L-tryptophan + O2
N-formyl-5-hydroxy-L-kynurenine
show the reaction diagram
-
-
-
-
?
5-hydroxy-tryptophan + O2
4-(2-amino-5-hydroxyphenyl)-2-(formylamino)-4-oxobutanoic acid
show the reaction diagram
-
-
-
?
5-hydroxytryptamine + O2
?
show the reaction diagram
-
-
-
-
?
5-hydroxytryptophan + O2
?
show the reaction diagram
-
-
-
-
?
5-methoxy-D,L-tryptophan + O2
?
show the reaction diagram
-
1 mM, 70% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
5-methoxy-DL-tryptophan + O2
5-methoxy-N-formyl-DL-kynurenine
show the reaction diagram
-
-
-
?
5-methyl-D,L-tryptophan + O2
?
show the reaction diagram
-
1 mM, 123% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
5-methyl-DL-tryptophan + O2
5-methyl-N-formyl-DL-kynurenine
show the reaction diagram
-
-
-
?
5-methyl-tryptophan + O2
4-(2-amino-5-methylphenyl)-2-(formylamino)-4-oxobutanoic acid
show the reaction diagram
-
-
-
?
5-methyltryptophan + O2
?
show the reaction diagram
-
-
-
-
?
6-fluoro-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 38% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
6-fluorotryptophan + O2
?
show the reaction diagram
-
-
-
-
?
6-methyl-DL-tryptophan + O2
6-methyl-N-formyl-DL-kynurenine
show the reaction diagram
-
-
-
?
6-methyl-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 72% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
6-nitro-L-tryptophan + O2
?
show the reaction diagram
-
1 mM, 2% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
7-methyl-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 18% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
alpha-methyl-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 35% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
alpha-N-methyl-L-tryptophan + O2
?
show the reaction diagram
-
1 mM, 21% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
beta-methyl-DL-tryptophan + O2
?
show the reaction diagram
-
1 mM, 32% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
D-Trp + O2
D-formylkynurenine
show the reaction diagram
D-Trp + O2
N-formyl-D-kynurenine
show the reaction diagram
-
-
-
-
?
D-tryptophan + O2
?
show the reaction diagram
-
-
-
-
?
D-tryptophan + O2
N-formyl-D-kynurenine
show the reaction diagram
L-5-hydroxytryptophan + O2
?
show the reaction diagram
-
-
-
-
?
L-Trp + O2
L-formylkynurenine
show the reaction diagram
L-tryptophan + O2
N-formyl-L-kynurenine
show the reaction diagram
L-tryptophan + O2
N-formylkynurenine
show the reaction diagram
-
-
-
-
?
L-tryptophan ethyl ester + O2
?
show the reaction diagram
-
1 mM, 14% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
L-tryptophan methyl ester + O2
?
show the reaction diagram
-
1 mM, 15% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
N-acetyl-L-tryptophan + O2
?
show the reaction diagram
-
1 mM, 3% activity relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
-
-
?
serotonin + O2
?
show the reaction diagram
-
-
-
-
?
Trp + O2
formylkynurenine
show the reaction diagram
-
-
-
-
?
tryptamine + O2
?
show the reaction diagram
-
-
-
-
?
tryptophan + O2
N-formylkynurenine
show the reaction diagram
-
if the cellular environment protects indoleamine 2,3-dioxygenase from oxidation to the ferric form, no additional electron donor might by required for indolamine 2,3-dioxygenase activity in intact tissues
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
D-tryptophan + O2
N-formyl-D-kynurenine
show the reaction diagram
L-Trp + O2
L-formylkynurenine
show the reaction diagram
induction by interferongamma
-
-
?
L-tryptophan + O2
N-formyl-L-kynurenine
show the reaction diagram
serotonin + O2
?
show the reaction diagram
-
-
-
?
tryptamine + O2
?
show the reaction diagram
-
-
-
?
5-hydroxy-L-tryptophan + O2
N-formyl-5-hydroxy-L-kynurenine
show the reaction diagram
-
-
-
-
?
D-tryptophan + O2
N-formyl-D-kynurenine
show the reaction diagram
L-Trp + O2
L-formylkynurenine
show the reaction diagram
L-tryptophan + O2
N-formyl-L-kynurenine
show the reaction diagram
serotonin + O2
?
show the reaction diagram
-
-
-
-
?
tryptamine + O2
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
additional information
-
O2-
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-kurarinone
non-competitive inhibitor
-
(1R,2S)-2-([[6-(trifluoromethyl)-1H-indazol-4-yl]amino]methyl)cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-chloro-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexyl acetate
-
-
(1R,2S)-2-[[(6-chloro-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1S,2R)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoic acid
-
-
(2S)-2'-methoxy kurarinone
non-competitive inhibitor
-
(3-hydroxyphenyl)(phenyl)methanone
-
(3R,4S and 3S,4R)-3-bromo-4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-3,4-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
alpha-lapachone
(3S,4S and 3R,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzyloxy)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S)-4-(benzylamino)-3,9-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(4E,4'E)-4,4'-bis(isopropylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
-
(4E,4'E)-4,4'-bis(pentan-3-ylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
-
(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)boronic acid
-
-
(E)-4-(isopropylimino)-2-methylnaphthalen-1(4H)-one
-
(R)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
-
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(1,4-dihydroxy-3-methylnaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
-
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
-
(S)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
-
1,2-naphthoquinone
-
1,4-naphtho-quinone
-
1,6,6-trimethyl-10,11-dioxo-2-(thiophen-3-yl)-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
0.02 mM, 29.3% inhibition
-
1,6,6-trimethyl-10,11-dioxo-2-phenyl-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
0.02 mM, 21.5% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl 1,3-thiazole-2-carboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl acetate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl benzoate
0.02 mM, 54.5% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclohexanecarboxylate
0.02 mM, 48.0% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclopropanecarboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl furan-3-carboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl hydroxyacetate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl thiophene-2-carboxylate
0.02 mM, 60.4% inhibition
-
1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
0.02 mM, 23.1% inhibition
1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
0.02 mM, 61.2% inhibition
-
1,6,6-trimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
-
-
1,6,6-trimethylphenanthro[1,2-b]furan-9,10,11(6H)-trione
0.02 mM, 52.7% inhibition
-
1-(1,3-benzothiazol-2-ylsulfanyl)-N,N-dimethylmethanamine
-
1-(2-hydroxy-4-methylphenyl)-3-(2-methoxyphenyl)propane-1,3-dione
-
-
1-(2-hydroxy-4-methylphenyl)-3-{2-[(propan-2-yl)oxy]phenyl}propane-1,3-dione
-
-
1-(2-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromothiophen-2-yl)-2-(3-methyl-1,4-dihydronaphthalen-2-yl)ethan-1-one
most potent inhibitor capable of blocking both indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) activity, with the IC50 value for BT-549 cells at 0.00342 mM
-
1-(3-chlorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-acetyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-methyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-bromophenyl)-2-[[5-(4-chlorophenyl)[1,3]thiazolo[2,3-c]-[1,2,4]triazol-3-yl]sulfanyl]ethanone
-
-
1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea
potent inhibitor. The basis for this high potency is a unique sulfur-aromatic interaction network formed by the thiourea moiety of the inhibitor with F163 and F226
-
1-(4-fluorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-acetylpiperazin-1-yl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-methoxypiperidin-1-yl)carbonyl]benzyl)-1Hnaphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
-
-
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-9,10,11(6H)-trione
0.02 mM, 68% inhibition
-
1-benzyl-5-phenyl-1H-imidazole
-
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
1-hydroxy-5,6-dimethoxy-3-oxo-2-phenyl-3H-indol-1-ium
-
1-methyl tryptophan
a tryptophan analogue. Galanal does not decrease the IkappaB-alpha expression in LPS-stimulated THP-1 cells
1-methyl-DL-tryptophan
-
1-methyl-L-tryptophan
1-methyl-tryptophan
non-competitive inhibitor
1-Methyltryptophan
-
1-oxo-2-phenyl-3H-1lambda5-indol-3-one
-
1-phenyl-2-(phenylsulfanyl)hydrazine
-
1-[(3-methylphenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(4-chlorophenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]proline
-
-
1-[3-(4-morpholinylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-(morpholin-4-ylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-[(4-methylpiperazin-1-yl)carbonyl]benzyl]-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-3-(4-methylphenyl)imidazolidin-2-one
-
-
1H-phenanthro[9,10-d]imidazole
-
2,1,3-benzothiadiazole
-
2,1,3-benzoxadiazole
-
2,2-dimethyl-1a,9b-dihydro-2H-benzo[g]oxireno[c]chromene-4,9-dione
-
2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
dehydro-alpha-lapachone
2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
2,2-dimethyl-3,4-epoxy-2H-naphtho[2,3-b]pyran-5,10-dione
-
2,3-dichloro-1,4-naphthoquinone
-
2-(1H-imidazol-4-yl)benzene-1,3-diol
-
2-(1H-imidazol-4-yl)benzenethiol
-
2-(1H-imidazol-4-yl)phenol
-
2-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
2-(1H-pyrazol-3-yl)phenol
-
2-(2-fluorophenyl)-1H-phenanthro[9,10-d]imidazole
-
2-(2-methylphenyl)-1-oxo-3H-1lambda5-indol-3-one
-
2-(2-methylphenyl)-1H-phenanthro[9,10-d]imidazole
-
2-(2-sulfanylidene-2,3-dihydro-1,3-thiazol-4-yl)benzoic acid
0.1 mM, 8% inhibition
-
2-(4-methoxyphenyl)-1-oxo-3H-1lambda5-indol-3-one
-
2-(4-methoxyphenyl)-3H-indol-3-one
-
2-(4-methoxyphenyl)-3H-indole
-
2-(4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]-triazol-1-yl)methyl]phenyl)-N,N-diethylacetamide
-
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
F5H5G0, P14902
poor inhibitor
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-hydroxyphenyl)acetate
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3,4-dihydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-cyanophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-hydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-cyanophenyl)acetate
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-hydroxyphenyl)acetate
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl phenylacetate
-
2-amino-3-hydroxy-N-(4-hydroxynaphthalen-1-yl)propanamide
-
2-amino-N-(4-hydroxynaphth-1-yl)acetamide
-
2-bromo-4-phenyl-1,3-thiazole
0.1 mM, 12% inhibition
-
2-chloro-4-phenyl-1,3-thiazole
0.1 mM, 0.5% inhibition
-
2-chloro-N-[[(4-chlorophenyl)sulfanyl]methyl]aniline
-
2-Hydroxy-1,4-naphthoquinone
-
2-mercaptobenzothiazole
-
2-methoxy-1,4-naphthoquinone
-
2-methyl-1,4-naphthoquinone
-
2-methylnaphthalene-1,4-dione
-
2-phenoxyaniline
-
2-phenyl-3H-indol-3-imine
-
2-phenyl-3H-indol-3-one
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(4-hydroxyphenyl)ethan-1-one
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-phenylethan-1-ol
-
-
2-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
2-[[(2,4-dichlorophenyl)methyl]sulfanyl]-6-methylpyrimidin-4(5H)-one
-
2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
2-[[5-cyano-4-(3-methoxyphenyl)-6-oxo-1,6-dihydropyrimidin-2-yl]sulfanyl]-N-[5-(propan-2-yl)thiophen-2-yl]butanamide
0.01 mM, 24.4% inhibition
-
3'-[[(2-chlorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
3'-[[(2-fluorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(2-methylpropyl)(propan-2-yl)amino][1,1'-biphenyl]-2-carboxylic acid
-
-
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(4aS,8aS)-octahydroquinolin-1(2H)-yl][1,1'-biphenyl]-2-carboxylic acid
-
-
3-(1H-1,2,3-triazol-5-yl)pyridine
-
3-(1H-imidazol-4-yl)benzaldehyde
-
3-(1H-imidazol-4-yl)benzenethiol
-
3-(1H-imidazol-4-yl)benzonitrile
-
3-(1H-imidazol-4-yl)phenol
-
3-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
3-(2-aminoethyl)-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 74.88% inhibition
-
3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazole
-
-
3-(4H-imidazol-4-yl)benzenethiol
-
3-hydroxy-2,2-dimethyl-4-(morpholin-4-yl)-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
3-hydroxy-4-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
3-phenylpyridine
-
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
3-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
3-[2-(cyclohexylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 64.95% inhibition
-
3-[2-(diethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 64.21% inhibition
-
3-[2-(dimethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 71.26% inhibition
-
3-[2-(ethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 81.67% inhibition
-
3-[2-(propylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 79.17% inhibition
-
3-[2-(tert-butylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 79.45% inhibition
-
3-[2-[(2-phenylethyl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 68.26% inhibition
-
3-[2-[(propan-2-yl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 63.75% inhibition
-
3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoic acid
EC50 is 183 nm
4'-(2,3-dimethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-([[4-(2-hydroxypropan-2-yl)phenyl]carbamoyl]amino)-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-[[(4-chlorophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-[[(4-cyanophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methoxyphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-ethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylanilino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-2-fluoro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-ethoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-5-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(3-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(cyclohexylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(dibutylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[(2,3-dihydro-1H-inden-4-yl)oxy]-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[bis(2-methylpropyl)amino]-N-(methanesulfonyl)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxamide
-
-
4'-[bis(cyclopropylmethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[cyclohexyl(methyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[cyclopentyl(ethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4-(1H-1,2,3-triazol-5-yl)pyridine
-
4-(1H-imidazol-4-yl)phenol
-
4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
4-(2,6-dimethoxyphenyl)-1H-imidazole
-
4-(2-(diethylamino)ethylamino)-1-naphthol
-
4-(2-(methylthio)phenyl)-1H-imidazole
-
4-(2-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 77% inhibition
-
4-(2-fluorophenyl)-1H-imidazole
-
4-(2-hydroxyethoxy)-1-naphthol
-
4-(2-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 53% inhibition
-
4-(2-sulfanylidene-2,3-dihydro-1,3-thiazol-4-yl)benzonitrile
0.1 mM, 8% inhibition
-
4-(3-(methylthio)phenyl)-1H-imidazole
-
4-(3-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 81% inhibition
-
4-(3-chlorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 40% inhibition
-
4-(3-chlorophenyl)-imidazole
-
-
4-(3-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 28% inhibition
-
4-(3-fluorophenyl)-1H-imidazole
-
4-(4-(methylthio)phenyl)-1H-imidazole
-
4-(4-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 100% inhibition
-
4-(4-chlorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 95% inhibition
-
4-(4-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 72% inhibition
-
4-(4-fluorophenyl)-1H-imidazole
-
4-(4-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 68% inhibition
-
4-(4-methylbenzene-1-sulfinyl)-7-nitro-2,1,3-benzoxadiazole
-
4-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 90% inhibition
-
4-(benzylamino)-1-naphthol
-
4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
4-(cyclohexylamino)-1-naphthol
-
4-(dimethylamino)naphthalen-1-ol
-
4-(ethylamino)-1-naphthol
-
4-(isobutylamino)-1-naphthol
-
4-(isopropylamino)-1-naphthol
-
4-(methanesulfonyl)-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
EC5 is 7846 nm
4-(methylamino)naphthalen-1-ol
-
4-(pent-3-ylamino)-1-naphthol
-
4-(propylamino)-1-naphthol
-
4-(pyridin-3-yl)-1,3-thiazole-2(3H)-thione
0.1 mM, 48% inhibition
-
4-(pyridin-4-yl)-1,3-thiazole-2(3H)-thione
0.1 mM, 21% inhibition
-
4-(tert-butylamino)naphthalen-1-ol
-
4-(thiophen-2-yl)-1H-imidazole
-
4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylic acid
-
-
4-amino-1-naphthol
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
4-bromo-N'-(4-bromophenyl)benzene-1-sulfonohydrazide
EC50 is 374 nm
4-chloro-2-(1H-1,2,3-triazol-4-yl)phenol
i.e. MMG-0358
-
4-chlorophenyl-1,2,3-triazol-4-amine
-
-
4-cyano-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
EC50 is 3404 nm
4-fluoro-2-(1H-pyrazol-3-yl)phenol
-
4-hydroxycarbazole
-
4-methoxy-1-naphthylamine
-
4-methoxy-3'-[(phenylcarbamoyl)amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(2-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(3-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-(2-propylphenoxy)[1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-(propan-2-yl)phenoxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-methyl-3-[(prop-2-yn-1-yl)oxy]phenoxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-nitro-2,1,3-benzothiadiazole
-
4-nitro-7-[(1-oxo-1lambda5--pyridin-2-yl)sulfanyl]-2,1,3-benzoxadiazole
-
4-phenyl-1,3-thiazol-2(3H)-one
0.1 mM, 15% inhibition
-
4-phenyl-1,3-thiazol-2-amine
4-phenyl-1,3-thiazole-2(3H)-thione
0.1 mM, 76% inhibition
-
4-phenyl-1,3-thiazole-2-thiol
-
4-phenyl-1H-imidazole
-
4-phenyl-imidazole
4-phenyl-imidazole coordinates transiently to the heme iron
4-phenylimidazole
4-[(1Z)-2-[(6-bromo-1H-indazol-4-yl)amino]-N-hydroxyethanimidoyl]phenol
-
-
4-[(2,4-dichlorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(3-chlorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
4-[(4-fluorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(4-methylphenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzamide
-
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
4-[2-(4-bromophenyl)hydrazinesulfonyl]benzoic acid
EC50 is 172 nm
4-[2-(methylsulfanyl)phenyl]-1H-imidazole
-
4-[3-(hydroxymethyl)phenyl]-1,3-thiazole-2(3H)-thione
0.1 mM, 16% inhibition
-
4-[3-(methylsulfanyl)phenyl]-1H-imidazole
-
4-[4-(trifluoromethyl)phenyl]-1,3-thiazole-2(3H)-thione
0.1 mM, 37% inhibition
-
4-[[(2,4-dichlorophenyl)methyl]sulfanyl]-6-methylpyrimidin-2(1H)-one
-
4-[[(2,4-dichlorophenyl)methyl]sulfanyl]pyrimidin-2(1H)-one
-
4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]phenol
-
-
5-(2-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 29% inhibition
-
5-(2-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 12% inhibition
-
5-(3-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 48% inhibition
-
5-(4-chlorophenyl)-3-[(2-methylpropyl)sulfanyl][1,3]thiazolo-[2,3-c][1,2,4]triazole
-
-
5-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 15% inhibition
-
5-(ethylamino)quinolin-8-ol
-
5-(isopropylamino)quinolin-8-ol
-
5-amino-8-hydroxyquinoline
-
5-chloro-1,3-benzothiazole-2(3H)-thione
-
5-hydroxy-1,4-naphthoquinone
-
5-phenyl-1,3-thiazole-2(3H)-thione
0.1 mM, 16% inhibition
-
5-phenyl-1H-1,2,3-triazole
-
5-[(2E)-2-[(4-bromophenyl)methylidene]hydrazinyl]-1-(naphthalen-1-yl)tetrazolidine
0.01 mM, 54.3% inhibition
-
5-[[(2,4-dichlorophenyl)methyl]sulfanyl]-1H-1,2,4-triazole
-
6-(4-iodo-2-methylanilino)-2,1,3-benzoxadiazole-5-carboxylic acid
-
6-(4-iodo-2-methylanilino)-3-oxo-2,1,3lambda~5~-benzoxadiazole-5-carboxylic acid
-
6-bromo-1H-indazol-4-amine
-
-
6-bromo-N-(cyclohexylmethyl)-1H-indazol-4-amine
-
-
6-bromo-N-[(1,4-dioxaspiro[4.5]decan-6-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(1R,2R)-2-hydroxycyclohexyl]-1H-indazole-4-carboxamide
-
-
6-bromo-N-[(pyridin-2-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(pyrrolidin-3-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(1S,2R)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(1S,2S)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
6-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
6-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-amino-2-[(2E)-3-(2H-1,3-benzodioxol-5-yl)prop-2-enoyl]-4-bromocyclohepta-2,4,6-trien-1-one
0.01 mM, 21.4% inhibition
-
7-fluoro-4-(2-fluoro-4-iodoanilino)-2,1,3-benzoxadiazole-5-carboxylic acid
-
7-hydroxy-1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
-
-
7-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-nitro-N-phenyl-2,1,3-benzoxadiazol-4-amine
-
8-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-2-[(1H-1,2,3-triazol-1-yl)methyl]indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-2-carbaldehyde
-
-
8-fluorotryptanthrin
-
-
8-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
8-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
9-fluorenone
-
9-hydroxy-1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
-
-
9-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
alpha-caryopterone
9-hydroxyfluorene
-
9-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
antisense oligonucleotide A06007H
+G*+A*+T*T*G*T*C*C*A*G*G*A*+G*+T*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06008H
+C*+T*+C*A*A*C*T*C*T*T*T*C*+T*+C*+G, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06030H
+A*+G*+G*C*G*C*T*G*T*G*A*C*T*+T*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06043H
+C*+C*+A*G*A*C*T*C*T*A*T*G*A*G*+A*+T*+C, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06044H
+G*+A*+G*A*T*G*A*T*C*A*A*T*G*C*+T*+G*+A, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06045H
+A*+G*+G*C*G*C*T*G*T*G*A*C*T*T*+G*+T*+G, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A07006H
+T*+G*+T*A*T*G*A*C*A*G*C*+C*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A07058H
+A*+T*+C*G*T*G*G*T*G*C*T*G*A*A*+C*+A*+A, (+) LNA-modified nucleotide, (*) PTO linkage
-
benzophenone
-
Benzothiazole
NC503425
brassinin
-
D-tryptophan
-
Dichlorophene
-
epacadostat
-
ethyl (2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoate
-
-
ethyl 1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl (2E)-but-2-enedioate
-
-
exiguamine A
-
galanal
competitive inhibitor, IC50 value of 45 nM in the cell-based assay. galanal interfered with the transcriptional function of the nuclear factor-kappaB and the interferon-gamma signaling pathway. These effects of galanal are important for immune response. The inhibitory effect of galanal on IDO1 activity is stronger than that of 1-methyl tryptophan, a tryptophan analogue
gamma-glutamyl-S-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)cysteinylglycine
-
INCB024360
0.01 mM, 97.59% inhibition
-
kushenol E
non-competitive inhibitor, the inhibitor might be useful in the development of immunotherapeutic agents against cancers
kushenol F
non-competitive inhibitor
-
L-tryptophan
-
menadione
menadione effectively inhibits L-Trp oxidation from reactions supported with ascorbaic acid/methylene blue
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]prolinate
-
-
methyl 2-methyl-5,10-dioxo-5,10-dihydro-2H-benzo[g]chromene-2-carboxylate
-
methyl 3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoate
EC50 is 465 nm
methyl 4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylate
-
-
methyl 7-fluoro-4-(2-fluoro-4-iodoanilino)-2,1,3-benzoxadiazole-5-carboxylate
-
methyl thiohydantoin-Trp
F5H5G0, P14902
-
methylene blue
addition of methylene blue (0-0.1 mM) to NADPH-cytochrome P450 reductase-supported D-Trp incubations (with or without cytochrome b5) leads to concentration-dependent inhibition of IDO activity, addition of methylene blue (0-0.03 mM) to NADPH-cytochrome P450 reductase-supported L-Trp oxidation reactions results in a switch from substrate inhibition kinetics to Michaelis-Menten with increasing methylene blue concentration decreasing the affinity of IDO for L-Trp
N'-(3-methylphenyl)-4-[[5-(trifluoromethyl)pyridin-2-yl]oxy]benzene-1-sulfonohydrazide
EC50 is 296 nm
N'-(4-bromophenyl)-4-cyanobenzene-1-sulfonohydrazide
EC50 is 134 nm
N'-(4-bromophenyl)-4-methoxybenzene-1-sulfonohydrazide
EC50 is 640 nm
N'-(4-bromophenyl)benzenesulfonohydrazide
EC50 is 128 nm
N'-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N-methyl-N-(4-methylphenyl)urea
-
-
N,N-dimethyl-1-[(4-phenyl-1,3-thiazol-2-yl)sulfanyl]methanamine
-
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
F5H5G0, P14902
a reversible inhibitor of IDO1. highly specific for IDO1 compared to IDO2, docking analysis with IDO1 and IDO2
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-3-carboximidamide
-
-
N-(4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-yl)-1,1,1-trifluoromethanesulfonamide
-
-
N-(4-bromophenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-bromophenyl)-N'-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]urea
-
-
N-(4-chlorophenyl)-2H-1,2,3-triazol-4-amine
i.e. Vertex-AT
-
N-(4-hydroxy-1-naphthyl)ethane-1,2-diaminium chloride
-
N-(4-hydroxy-1-naphthyl)propane-1,3-diaminium chloride
-
N-(4-hydroxynaphthalen-1-yl)pyrrolidine-2-carboxamide
-
N-(4-methoxyphenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-methylphenyl)-2,1,3-benzoxadiazol-4-amine
-
N-(4-methylphenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-[2-[4-(trifluoromethyl)phenyl]hydrazinesulfonyl]phenyl)acetamide
EC50 is 181 nm
N-(4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexylidene)hydroxylamine
-
-
N-(phenyldisulfanyl)aniline
-
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
F5H5G0, P14902
poor inhibitor
N-methyl-L-Trp
F5H5G0, P14902
-
N-phenyl-p-phenylenediamine
-
N-[(1,3-benzothiazol-2-yl)sulfanyl]-2-nitrobenzene-1-sulfonamide
0.01 mM, 35.9% inhibition
-
N-[(azetidin-3-yl)methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[(E)-(2-phenyl-3H-indol-3-yl)methylidene]hydroxylamine
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-3-methoxy-N-methylbenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-4-methoxy-N-methylbenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-(4-cyanophenyl)acetamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-methyl-4-nitrobenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-methylacetamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-phenylacetamide
-
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]-2,2-dimethylpropanamide
0.01 mM, 72.35% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]acetamide
0.01 mM, 57.47% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzamide
0.01 mM, 65.72% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzenesulfonamide
0.01 mM, 59.71% inhibition
-
N-[4-(2-phenylhydrazinesulfonyl)phenyl]acetamide
EC50 is over 0.010 mM
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(2-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(3-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methoxyphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-phenylurea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(difluoromethoxy)phenyl]urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(trifluoromethoxy)phenyl]urea
-
-
N-[4-[2-(2,4-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(3,4-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 350 nm
N-[4-[2-(3,5-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 508 nm
N-[4-[2-(3,5-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2229 nm
N-[4-[2-(3-bromo-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2494 nm
N-[4-[2-(3-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 7563 nm
N-[4-[2-(3-chloro-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2588 nm
N-[4-[2-(3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]benzoyl]glycine
EC50 is 571 nm
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 241 nm
N-[4-[2-(4-bromo-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 187 nm
N-[4-[2-(4-bromo-3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 130 nm
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-chlorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-cyanophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-fluorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methoxyphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methylphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-chlorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methoxyphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methylphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-butylurea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-cyclohexylurea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[3-(1H-tetrazol-5-yl)phenyl]urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[4-(1H-tetrazol-5-yl)phenyl]urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 85 nm
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]butanamide
EC50 is 187 nm
N-[4-[2-(4-chloro-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 84 nm
N-[4-[2-(4-chlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 142 nm
N-[4-[2-(4-cyanophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 1393 nm
N-[4-[2-(4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 609 nm
N-[4-[2-(4-methoxyphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(4-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 1171 nm
N-[4-[2-(4-sulfamoylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 3118 nm
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-2-(4-methylphenyl)acetamide
-
-
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
-
-
N-[[(1S,2R)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(1S,2S)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-2-nitroaniline
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-4-methylaniline
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-4-nitroaniline
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-2-hydroxyacetamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-4-oxobutanamide
0.001 mM, 97% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-(phenylacetyl)glycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-(phenylacetyl)glycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(2-nitrophenyl)acetyl]glycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(3-nitrophenyl)acetyl]glycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(4-nitrophenyl)acetyl]glycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(2-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3,4-dihydroxyphenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-hydroxyphenyl)acetyl]-N2-methylglycinamide
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-cyanophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-hydroxyphenyl)acetyl]-N2-methylglycinamide
-
-
N2-[(2S)-2-amino-2-phenylacetyl]-N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]glycinamide
-
-
naphthalene-1,4-diol
-
naphthalene-1,4-dione
-
NO
can inhibit hIDO by directly binding to the heme iron
noranhydroicaritin
non-competitive inhibitor
norharman
-
norharmane
NHM, noncompetitive versus L-Trp and competitive versus O2
NSC275428
-
primaquine
-
propan-2-yl 4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoate
-
-
quinolin-8-ol
-
S-(2-chlorophenyl) (4-chlorophenyl)carbamothioate
-
sophoraflavanone B
non-competitive inhibitor
streptovaricin C
NSC19990
tert-butyl 3-[[(6-bromo-1H-indazol-4-yl)amino]methyl]pyrrolidine-1-carboxylate
-
-
tert-butyl [2-(4,7-dioxo-5-phenyl-4,7-dihydro-1H-indol-3-yl)ethyl]carbamate
0.01 mM, 56.38% inhibition
-
tert-butyl [2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 66.51% inhibition
-
tert-butyl [2-[4,7-dioxo-5-(pyridin-4-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 12.42% inhibition
-
tert-butyl [2-[5-(2-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 67.30% inhibition
-
tert-butyl [2-[5-(2-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 63.23% inhibition
-
tert-butyl [2-[5-(4-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 43.34% inhibition
-
tert-butyl [2-[5-(4-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 34.45% inhibition
-
tert-butyl [2-[5-(4-methylphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 25.52% inhibition
-
Thiourea
NSC201634
vitamin K3
menadione
[3-(4-bromobenzoyl)-1,2-oxazol-4-yl](naphthalen-2-yl)methanone
0.01 mM, 28.4% inhibition
-
[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenoxy]acetic acid
EC50 is 152 nm
(10Z,13Z)-nonadecadienoic acid
-
32% inhibition at 0.02 mM
(11Z,14Z)-eicosadienoic acid
-
42% inhibition at 0.02 mM
(11Z,14Z,17Z)-eisosatrienoic acid
-
19% inhibition at 0.02 mM
(12Z,15Z)-heneicosadienoic acid
-
39% inhibition at 0.02 mM
(13Z,16Z)-docosadienoic acid
-
39% inhibition at 0.02 mM
(13Z,16Z,19Z)-docosatrienoic acid
-
52% inhibition at 0.02 mM
(2,4-dichlorophenyl)methanethiol
-
-
(2-chlorophenyl)methanethiol
-
-
(3,4-dichlorophenyl)methanethiol
-
-
(4-chlorophenyl)methanethiol
-
-
(4-chlorophenyl)methanol
-
-
(4-fluorophenyl)methanethiol
-
-
(4-methoxyphenyl)methanethiol
-
-
(4-methylphenyl)methanethiol
-
-
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid
-
48% inhibition at 0.02 mM
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
-
35% inhibition at 0.02 mM
(5Z,8Z)-7,7-dimethyl-5,8-eicosadienoic acid
-
29% inhibition at 0.02 mM
(5Z,8Z)-eicosadienoic acid
-
42% inhibition at 0.02 mM
(5Z,8Z,11Z)-eisosatrienoic acid
-
45% inhibition at 0.02 mM
(5Z,8Z,11Z,14Z)-eicosatetraenoic acid
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid
-
19% inhibition at 0.02 mM
(7Z,10Z,13Z,16Z)-docosatetraenoic acid
-
42% inhibition at 0.02 mM
(8Z,11Z,14Z)-eisosatrienoic acid
-
68% inhibition at 0.02 mM
(9E,11Z)-octadecadienoic acid
-
26% inhibition at 0.02 mM
(9E,12E)-octadecadienoic acid
-
23% inhibition at 0.02 mM
(9Z,12Z)-octadecadienoic acid
-
16% inhibition at 0.02 mM
(9Z,12Z,15Z)-octadecatrienoic acid
-
23% inhibition at 0.02 mM
1-(4-chlorobenzyl)urea
-
-
1-(4-chlorophenyl)methanamine
-
-
1-(4-chlorophenyl)thiourea
-
-
1-benzofuran-DL-tryptophan
-
1 mM, 43% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-benzothiophene-DL-tryptophan
-
1 mM, 16% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-L-methyltryptophan
-
-
1-methyl-D-tryptophan
1-methyl-DL-Trp
1-methyl-DL-tryptophan
1-methyl-L-tryptophan
1-methyl-tryptophan
1-Methyltryptophan
1-[2-(4-chlorophenyl)ethyl]thiourea
-
-
15-deoxy-DELTA12,14-prostaglandin
-
-
1H-benzotriazole
-
-
2,4-dichlorobenzyl carbamimidothioate hydrobromide
-
-
2-(1H-imidazol-4-yl)phenol
-
-
2-(2-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(3-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(4-chlorophenyl)ethanamine
-
-
2-(4-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
F5H5G0, P14902
poor inhibitor
2-bromo-L-tryptophan
-
1 mM, 11% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-chloro-L-tryptophan
-
1 mM, 20% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-chlorobenzyl carbamimidothioate hydrochloride
-
-
2-hydroxy-L-tryptophan
-
1 mM, 30% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-hydroxygarveatin E
-
-
2-hydroxygarvin A
-
-
2-methylindole
-
3,4-dichlorobenzyl carbamimidothioate hydrochloride
-
-
3-(1H-1,2,3-triazol-5-yl)pyridine
-
-
3-chlorobenzyl carbamimidothioate hydrochloride
-
-
4-(phenylcarbonyl)benzyl carbamimidothioate hydrobromide
-
-
4-(propan-2-yl)benzyl carbamimidothioate hydrobromide
-
-
4-(trifluoromethyl)benzyl carbamimidothioate hydrochloride
-
-
4-amino-1,2,3-oxadiazole-3-carboximidamide
-
-
4-amino-1,2,5-oxadiazole-3-carboximidamide
-
competitive
4-amino-N'-hydroxy-N-(3-isopropylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-(3-methoxyphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-(3-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-phenyl-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(2-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-bromophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-chlorophenyl)-1,2,5-oxadiazole-3-carbohydrazonamide
-
-
4-amino-N-(3-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-ethylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-tert-butylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(4-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-benzyl-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-bromo-5-(4-methylphenyl)-1H-1,2,3-triazole
-
-
4-bromobenzyl carbamimidothioate hydrobromide
-
-
4-chlorobenzenesulfonic acid
-
-
4-chlorobenzenethiol
-
-
4-chlorobenzyl carbamimidothioate hydrochloride
-
-
4-chlorobenzyl N,N'-dimethylcarbamimidothioate - 1-chlorotetraoxidane (1:1)
-
-
4-cyanobenzyl carbamimidothioate hydrobromide
-
-
4-ethylbenzyl carbamimidothioate hydrochloride
-
-
4-fluorobenzyl carbamimidothioate hydrochloride
-
-
4-iodo-5-phenyl-1H-1,2,3-triazole
-
-
4-methoxybenzyl carbamimidothioate hydrochloride
-
-
4-methyl-DL-tryptophan
-
1 mM, 26% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
4-methylbenzyl carbamimidothioate hydrochloride
-
-
4-nitro-5-(4-nitrophenyl)-1H-1,2,3-triazole
-
-
4-nitrobenzyl carbamimidothioate hydrochloride
-
-
4-phenylimidazole
-
-
4-tert-butylbenzyl carbamimidothioate hydrobromide
-
-
4-[(carbamimidoylsulfanyl)methyl]benzoic acid hydrochloride
-
-
5-(2-bromophenyl)-1H-1,2,3-triazole
-
-
5-(2-chlorophenyl)-1H-1,2,3-triazole
-
-
5-(2-methoxyphenyl)-1H-1,2,3-triazole
-
-
5-(4-bromophenyl)-1H-1,2,3-triazole
-
-
5-(4-chlorophenyl)-1H-1,2,3-triazole
-
-
5-(4-fluorophenyl)-1H-1,2,3-triazole
-
-
5-(4-methoxyphenyl)-1H-1,2,3-triazole
-
-
5-benzyloxy-DL-tryptophan
-
1 mM, 2% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-bromo-DL-tryptophan
-
1 mM, 56% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-fluoro-DL-tryptophan
-
1 mM, 32% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-hydroxy-L-Trp
-
5-hydroxy-L-tryptophan
-
1 mM, 12% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-methoxy-DL-tryptophan
-
1 mM, 35% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-methyl-DL-tryptophan
-
1 mM, 6% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-phenyl-1H-1,2,3-triazole
-
-
6-fluoro-DL-tryptophan
-
1 mM, 54% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-methyl-DL-tryptophan
-
1 mM, 20% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-nitro-D-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-nitro-L-tryptophan
-
1 mM, competitive inhibition, 52% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
7-methyl-DL-tryptophan
-
1 mM, 36% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
alpha-methyl-DL-tryptophan
-
1 mM, 1% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
alpha-N-methyl-L-tryptophan
-
1 mM, 33% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
annulin A
-
-
annulin B
-
-
arachidonate
-
-
baicalein
-
uncompetitive reversible potent IDO-1 inhibitor
benzyl carbamimidothioate hydrochloride
-
-
Berberine
-
uncompetitive reversible potent IDO-1 inhibitor
beta-carboline
-
-
beta-Methyl-DL-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
brassinin
-
-
cyanide
D-tryptophan
low inhibition
epigallocatechin gallate
-
-
ethyl 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-carboxylate
-
-
exiguamine A
exiguamine B
-
-
garveatin A
-
-
garveatin C
-
-
garveatin E
-
-
imidodicarbonimidic diamide, N-methyl-N''-9-phenanthrenyl-, monohydrochloride
-
-
Indole-3-propionic acid
-
-
interleukin-4
-
-
-
Jatrorrhizine
-
irreversible potent IDO-1 inhibitor
L-tryptophan
L-tryptophan ethyl ester
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
L-tryptophan methyl ester
-
1 mM, 30% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
menadione
-
-
methyl 4-[(carbamimidoylsulfanyl)methyl]benzenesulfinate hydrobromide
-
-
methyl N-(4-chlorophenyl)carbamimidothioate hydroiodide
-
-
methyl N-[2-(4-chlorophenyl)ethyl]carbamimidothioate hydroiodide
-
-
methyl thiohydantoin-Trp
F5H5G0, P14902
-
methyl-thiohydantoin tryptophan
-
-
methyl-thiohydantoin-L-tryptophan
-
competitive inhibitor
methyl-thiohydantoin-tryptophan
-
limited selectivity towards indoleamine 2,3-dioxygenase
mitomycin C
-
-
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
F5H5G0, P14902
a reversible inhibitor of IDO1. highly specific for IDO1 compared to IDO2, docking analysis with IDO1 and IDO2
N-acetyl-L-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
F5H5G0, P14902
poor inhibitor
N-methyl-L-Trp
F5H5G0, P14902
-
N1-acetyl-N2-formyl-5-methoxykynurenine
-
norharman
NSC 401366
-
competitive with respect to tryptophan
palmatine
-
irreversible potent IDO-1 inhibitor
phenylmethanethiol
-
-
prostaglandin (19R)-hydroxy-PGE2
-
-
prostaglandin 13,14-dihydro-15-oxo-PGE2
-
-
prostaglandin 15-oxo-PGE2
-
-
prostaglandin 15-oxo-PGF2alpha
-
-
prostaglandin 20-hydroxy PGE2
-
-
prostaglandin DELTA12-PGJ2
-
-
prostaglandin PGA2
-
-
prostaglandin PGD2
-
-
prostaglandin PGD2 ethanolamide
-
-
prostaglandin PGE2
-
-
prostaglandin PGE2 ethanolamide
-
-
prostaglandin PGF2beta
-
-
prostaglandin PGG2
-
-
prostaglandin PGH2
-
-
prostaglandin PGJ2
-
-
sodium 4-chlorobenzenesulfinate
-
-
transforming growth factor-beta
-
inhibits expression in skin and synovial fibroblasts
-
tryptamine
[4-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[4-(1-oxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[5-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[5-(1-oxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
ascorbic acid
cytochrome b5
-
-
L-ascorbate
required
methylene blue
NADPH-cytochrome P450 reductase
-
-
1-(1H-indol-3-yl)ethanol
-
effector
alpha-interferon
-
ascorbate
-
promotes IDO peroxidase turnover by reducing Compound II
ascorbic acid
beta-interferon
-
induces IDO expression in monocytes
-
gamma-interferon
-
hydrogen peroxide
-
activates the peroxidase function of IDO to induce protein oxidation and inhibit dioxygenase activity
lipopolysaccharide
-
induces IDO expression in monocytes
methylene blue
tumor-necrosis-factor-alpha
-
costimulation with gamma-interferon
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.66
1-methyl-D-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
0.07
1-methyl-L-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
0.006
5-fluoro-DL-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
0.017 - 0.68
5-hydroxy-L-tryptophan
0.098
5-methyl-DL-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
0.296 - 5.2
D-tryptophan
0.00072 - 0.1815
L-tryptophan
0.747
1-methyl-D-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.062 - 0.696
1-methyl-L-tryptophan
1.768
5-fluoro-DL-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.006 - 0.36
5-fluoro-tryptophan
0.1 - 0.44
5-hydroxy-L-tryptophan
0.017
5-hydroxy-tryptophan
-
0.113 - 0.547
5-methoxy-DL-tryptophan
0.088 - 1.57
5-methyl-DL-tryptophan
0.098
5-methyl-tryptophan
-
0.056 - 3.457
6-methyl-DL-tryptophan
5 - 5.2
D-Trp
0.0019 - 5
D-tryptophan
0.02 - 0.043
L-Trp
0.0056 - 6.809
L-tryptophan
0.042
O2
-
-
additional information
additional information
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.095
1-methyl-D-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
0.062
1-methyl-L-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
0.76
5-fluoro-DL-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
0.025
5-hydroxy-L-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
3.78
5-methyl-DL-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
2.7
D-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
0.87 - 12
L-tryptophan
0.0052
1-methyl-D-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.011 - 0.064
1-methyl-L-tryptophan
0.049
5-fluoro-DL-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.18 - 0.76
5-fluoro-tryptophan
0.065
5-hydroxy-L-tryptophan
-
-
0.025
5-hydroxy-tryptophan
-
0.161
5-methoxy-DL-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.36
5-methyl-DL-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
3.78
5-methyl-tryptophan
-
0.108
6-methyl-DL-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
2.07
D-Trp
-
-
0.0103 - 5.9
D-tryptophan
1.55
L-Trp
-
-
0.04 - 6.12
L-tryptophan
2.9
O2
-
-
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
70.9 - 1200
L-tryptophan
0.007
1-methyl-D-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.016
1-methyl-L-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.028
5-fluoro-DL-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.294
5-methoxy-DL-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.229
5-methyl-DL-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.031
6-methyl-DL-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.0028
D-tryptophan
pH 7.5, 25°C, recombinant enzyme IDO2
0.015 - 4.5
L-tryptophan
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000061
(3R,4S and 3S,4R)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
0.00007
(3S,4S and 3R,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
0.000066
(3S,4S)-4-(benzylamino)-3,9-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
0.0052 - 0.062
1-methyl-L-tryptophan
0.034
1-Methyltryptophan
-
0.0089
2-(1H-imidazol-4-yl)phenol
-
0.0053
3-(1H-imidazol-4-yl)benzenethiol
-
0.0048
3-(4H-imidazol-4-yl)benzenethiol
-
0.00012
annulin B
-
0.543
D-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
0.05
L-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO1
1.28
norharman
37°C, pH 6.5
0.012 - 0.03
norharmane
0.1 - 3.3
1-methyl-D-tryptophan
0.023
1-methyl-DL-Trp
-
0.068
1-methyl-DL-tryptophan
-
-
0.019 - 0.3
1-methyl-L-tryptophan
0.034 - 0.068
1-Methyltryptophan
0.0014
2-hydroxygarveatin E
-
25°C, pH 6.5
0.0023
2-hydroxygarvin A
-
25°C, pH 6.5
0.158
2-methylindole
-
0.0015
4-amino-1,2,5-oxadiazole-3-carboximidamide
-
-
0.018
5-(2-bromophenyl)-1H-1,2,3-triazole
-
pH 6.5, 37°C, recombinant enzyme
0.0145
5-(2-chlorophenyl)-1H-1,2,3-triazole
-
pH 6.5, 37°C, recombinant enzyme
0.072
5-hydroxy-L-Trp
-
0.0225
5-phenyl-1H-1,2,3-triazole
-
pH 6.5, 37°C, recombinant enzyme
0.18
6-nitro-L-tryptophan
-
1 mM, competitive inhibition, 52% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
0.00014 - 0.00069
annulin A
0.00012
annulin B
-
25°C, pH 6.5
0.215
baicalein
-
pH and temperature not specified in the publication
0.008
Berberine
-
pH and temperature not specified in the publication
12
D-tryptophan
pH 6.5, 25°C, recombinant enzyme IDO2
0.00021
exiguamine A
-
-
0.0032
garveatin A
-
25°C, pH 6.5
0.0012
garveatin C
-
25°C, pH 6.5
0.0031
garveatin E
-
25°C, pH 6.5
0.0015
imidodicarbonimidic diamide, N-methyl-N''-9-phenanthrenyl-, monohydrochloride
-
-
0.17
L-tryptophan
-
-
0.176
norharman
-
-
0.255
tryptamine
-
0.367
[4-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
0.0871
[4-(1-oxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
0.197
[5-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
0.0763
[5-(1-oxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
additional information
additional information
review article sumarizing data of many inhibitors of indoleamine 2,3-dioxygenase
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0234
(-)-kurarinone
Homo sapiens
pH 6.5, 37°C
-
0.00317
(1R,2S)-2-([[6-(trifluoromethyl)-1H-indazol-4-yl]amino]methyl)cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00123
(1R,2S)-2-[[(5-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.03801
(1R,2S)-2-[[(5-bromo-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.06604
(1R,2S)-2-[[(5-chloro-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00064
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00578
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexyl acetate
Homo sapiens
22°C, pH 6.5
-
0.1783
(1R,2S)-2-[[(6-chloro-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00187
(1R,2S)-2-[[(6-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00285
(1S,2R)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.00012
(2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.0314
(2S)-2'-methoxy kurarinone
Homo sapiens
pH 6.5, 37°C
-
0.5
(3-hydroxyphenyl)(phenyl)methanone
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000512
(3R,4S and 3S,4R)-3-bromo-4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000361
(3R,4S and 3S,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00396
(3R,4S and 3S,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000183
(3R,4S and 3S,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000252
(3R,4S and 3S,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00345
(3R,4S and 3S,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000082
(3R,4S and 3S,4R)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.0015
(3S,4S and 3R,4R)-3,4-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
alpha-lapachone
0.0011
(3S,4S and 3R,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000976
(3S,4S and 3R,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000186
(3S,4S and 3R,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.000055
(3S,4S and 3R,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00109
(3S,4S and 3R,4R)-4-(benzyloxy)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00212
(3S,4S and 3R,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00013
(3S,4S)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00045
(4E,4'E)-4,4'-bis(isopropylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00052
(4E,4'E)-4,4'-bis(pentan-3-ylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00179
(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)boronic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.0002
(E)-4-(isopropylimino)-2-methylnaphthalen-1(4H)-one
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.09
(R)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00034
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(1,4-dihydroxy-3-methylnaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
Homo sapiens
-
0.00088
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
Homo sapiens
-
0.06
(S)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0071
1,2-naphthoquinone
Homo sapiens
-
0.00099
1,4-naphtho-quinone
Homo sapiens
-
0.0293
1,6,6-trimethyl-10,11-dioxo-2-(thiophen-3-yl)-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
Homo sapiens
37°C, pH 6.5
-
0.0215
1,6,6-trimethyl-10,11-dioxo-2-phenyl-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
Homo sapiens
37°C, pH 6.5
-
0.00571
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl 1,3-thiazole-2-carboxylate
Homo sapiens
37°C, pH 6.5
-
0.00372
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl acetate
Homo sapiens
37°C, pH 6.5
-
0.00705
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclopropanecarboxylate
Homo sapiens
37°C, pH 6.5
-
0.0046
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl furan-3-carboxylate
Homo sapiens
37°C, pH 6.5
-
0.00274
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl hydroxyacetate
Homo sapiens
37°C, pH 6.5
-
0.00472
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
Homo sapiens
37°C, pH 6.5
-
0.00084
1,6,6-trimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
Homo sapiens
37°C, pH 6.5
-
0.05
1-(1,3-benzothiazol-2-ylsulfanyl)-N,N-dimethylmethanamine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000809
1-(2-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.003163
1-(3-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000767
1-(3-chlorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000602
1-(3-[(4-acetyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00064
1-(3-[(4-methyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.01
1-(4-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
above, pH 8.0, 37°C
0.000339
1-(4-bromophenyl)-2-[[5-(4-chlorophenyl)[1,3]thiazolo[2,3-c]-[1,2,4]triazol-3-yl]sulfanyl]ethanone
Homo sapiens
pH and temperature not specified in the publication
-
0.0000164
1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea
Homo sapiens
pH and temperature not specified in the publication
-
0.002587
1-(4-fluorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00177
1-(4-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.001097
1-(4-[(4-acetylpiperazin-1-yl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.001593
1-(4-[(4-methoxypiperidin-1-yl)carbonyl]benzyl)-1Hnaphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.00037
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
Homo sapiens
37°C, pH 6.5
-
0.032
1-benzyl-5-phenyl-1H-imidazole
Homo sapiens
-
0.000081
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
Homo sapiens
22°C, pH 6.5
0.4233
1-methyl-tryptophan
Homo sapiens
pH 6.5, 37°C
0.004612
1-[(3-methylphenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.01
1-[(4-chlorophenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
above, pH 8.0, 37°C
0.00057
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.00048
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.00055
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]proline
Homo sapiens
pH and temperature not specified in the publication
-
0.000936
1-[3-(4-morpholinylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000982
1-[4-(morpholin-4-ylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.002069
1-[4-[(4-methylpiperazin-1-yl)carbonyl]benzyl]-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
Homo sapiens
pH 8.0, 37°C
0.000028
1-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-3-(4-methylphenyl)imidazolidin-2-one
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00495
2,2-dimethyl-1a,9b-dihydro-2H-benzo[g]oxireno[c]chromene-4,9-dione
Homo sapiens
pH and temperature not specified in the publication
0.000214
2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
dehydro-alpha-lapachone
0.00434
2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00495
2,2-dimethyl-3,4-epoxy-2H-naphtho[2,3-b]pyran-5,10-dione
Homo sapiens
-
0.00028
2,3-dichloro-1,4-naphthoquinone
Homo sapiens
-
0.0053
2-(1H-imidazol-4-yl)benzene-1,3-diol
Homo sapiens
-
0.025
2-(1H-imidazol-4-yl)benzenethiol
Homo sapiens
-
0.0048
2-(1H-imidazol-4-yl)phenol
Homo sapiens
-
0.035
2-(1H-pyrazol-3-yl)phenol
Homo sapiens
-
0.000922
2-(4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]-triazol-1-yl)methyl]phenyl)-N,N-diethylacetamide
Homo sapiens
pH 8.0, 37°C
0.25
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
Homo sapiens
F5H5G0, P14902
above, pH 7.0, 22°C, IDO1
0.00087
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-hydroxyphenyl)acetate
Homo sapiens
pH and temperature not specified in the publication
-
0.00034
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-cyanophenyl)acetate
Homo sapiens
pH and temperature not specified in the publication
-
0.0002
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-hydroxyphenyl)acetate
Homo sapiens
pH and temperature not specified in the publication
-
0.00058
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl phenylacetate
Homo sapiens
pH and temperature not specified in the publication
-
0.4
2-amino-3-hydroxy-N-(4-hydroxynaphthalen-1-yl)propanamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.105
2-amino-N-(4-hydroxynaphth-1-yl)acetamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.675
2-Hydroxy-1,4-naphthoquinone
Homo sapiens
-
0.05
2-mercaptobenzothiazole
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00072
2-methoxy-1,4-naphthoquinone
Homo sapiens
-
0.0011
2-methyl-1,4-naphthoquinone
Homo sapiens
-
0.0011
2-methylnaphthalene-1,4-dione
Homo sapiens
pH and temperature not specified in the publication
1
2-phenoxyaniline
Homo sapiens
IC50 above 1.0 mM, in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.01309
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(3-chlorophenyl)ethan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.1371
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(4-hydroxyphenyl)ethan-1-one
Homo sapiens
22°C, pH 6.5
-
0.01833
2-[(6-bromo-1H-indazol-4-yl)amino]-2-(3-chlorophenyl)ethan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.04287
2-[(6-bromo-1H-indazol-4-yl)amino]-2-phenylethan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.0000787
2-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.00412
2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
Homo sapiens
22°C, pH 6.5
-
0.000022
3'-[[(2-chlorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00005
3'-[[(2-fluorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000042
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(2-methylpropyl)(propan-2-yl)amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000159
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(4aS,8aS)-octahydroquinolin-1(2H)-yl][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.68
3-(1H-1,2,3-triazol-5-yl)pyridine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.825
3-(1H-imidazol-4-yl)benzaldehyde
0.0076
3-(1H-imidazol-4-yl)benzenethiol
Homo sapiens
-
0.041
3-(1H-imidazol-4-yl)benzonitrile
Homo sapiens
-
0.365
3-(1H-imidazol-4-yl)phenol
Homo sapiens
-
0.00051
3-(2-aminoethyl)-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.000379
3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazole
Homo sapiens
pH and temperature not specified in the publication
-
0.0077
3-(4H-imidazol-4-yl)benzenethiol
Homo sapiens
-
0.00036
3-hydroxy-2,2-dimethyl-4-(morpholin-4-yl)-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.00396
3-hydroxy-4-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.161
3-phenylpyridine
Homo sapiens
-
0.000977
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
Homo sapiens
pH 8.0, 37°C
0.001242
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
Homo sapiens
pH 8.0, 37°C
0.000065
3-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.0015
3-[2-(cyclohexylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00226
3-[2-(diethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0005
3-[2-(dimethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00016
3-[2-(ethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00088
3-[2-(propylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00056
3-[2-(tert-butylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.004
3-[2-[(2-phenylethyl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00051
3-[2-[(propan-2-yl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.000141
3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.00016
4'-(2,3-dimethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0024
4'-(2-chlorophenoxy)-3'-([[4-(2-hydroxypropan-2-yl)phenyl]carbamoyl]amino)-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00083
4'-(2-chlorophenoxy)-3'-[[(4-chlorophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.006
4'-(2-chlorophenoxy)-3'-[[(4-cyanophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0021
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methoxyphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00084
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00054
4'-(2-ethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0006
4'-(2-tert-butylanilino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0045
4'-(2-tert-butylphenoxy)-2-fluoro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00007
4'-(2-tert-butylphenoxy)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0024
4'-(2-tert-butylphenoxy)-4-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00012
4'-(2-tert-butylphenoxy)-4-ethoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00035
4'-(2-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00025
4'-(2-tert-butylphenoxy)-5-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00069
4'-(3-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000504
4'-(cyclohexylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000045
4'-(dibutylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00028
4'-[(2,3-dihydro-1H-inden-4-yl)oxy]-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000013
4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000661
4'-[bis(2-methylpropyl)amino]-N-(methanesulfonyl)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxamide
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000348
4'-[bis(cyclopropylmethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000014
4'-[cyclohexyl(methyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000023
4'-[cyclopentyl(ethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.005
4-(1H-1,2,3-triazol-5-yl)pyridine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
1.2
4-(1H-imidazol-4-yl)phenol
Homo sapiens
-
0.734
4-(2,6-dimethoxyphenyl)-1H-imidazole
Homo sapiens
-
0.003
4-(2-(diethylamino)ethylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.038
4-(2-(methylthio)phenyl)-1H-imidazole
Homo sapiens
-
0.179
4-(2-fluorophenyl)-1H-imidazole
0.0125
4-(2-hydroxyethoxy)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.073
4-(3-(methylthio)phenyl)-1H-imidazole
Homo sapiens
-
0.00033
4-(3-chlorophenyl)-imidazole
Homo sapiens
pH and temperature not specified in the publication
-
0.06
4-(3-fluorophenyl)-1H-imidazole
Homo sapiens
-
0.209
4-(4-(methylthio)phenyl)-1H-imidazole
Homo sapiens
-
0.0034
4-(4-bromophenyl)-1,3-thiazole-2(3H)-thione
Homo sapiens
pH 6.5, 22°C
-
0.0026
4-(4-chlorophenyl)-1,3-thiazole-2(3H)-thione
Homo sapiens
pH 6.5, 22°C
-
0.123
4-(4-fluorophenyl)-1H-imidazole
Homo sapiens
-
0.0059
4-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
Homo sapiens
pH 6.5, 22°C
-
0.0025
4-(benzylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000055 - 0.00025
4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
0.00013
4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.015
4-(cyclohexylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
1
4-(dimethylamino)naphthalen-1-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.016
4-(ethylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.025
4-(isobutylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0025
4-(isopropylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000043
4-(methanesulfonyl)-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.0125
4-(methylamino)naphthalen-1-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0035
4-(pent-3-ylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0045
4-(propylamino)-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.004
4-(tert-butylamino)naphthalen-1-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.422
4-(thiophen-2-yl)-1H-imidazole
0.03022
4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylic acid
Homo sapiens
22°C, pH 6.5
-
0.003
4-amino-1-naphthol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000085
4-bromo-N'-(4-bromophenyl)benzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.00011
4-chlorophenyl-1,2,3-triazol-4-amine
Homo sapiens
pH and temperature not specified in the publication
-
0.000059
4-cyano-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.026
4-fluoro-2-(1H-pyrazol-3-yl)phenol
0.4
4-hydroxycarbazole
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0055
4-methoxy-1-naphthylamine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.000062
4-methoxy-3'-[(phenylcarbamoyl)amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000049
4-methoxy-3'-[[(2-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0001
4-methoxy-3'-[[(3-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00033
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-(2-propylphenoxy)[1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0001
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00034
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-(propan-2-yl)phenoxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00005
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-methyl-3-[(prop-2-yn-1-yl)oxy]phenoxy][1,1'-biphenyl]-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
1
4-phenyl-1,3-thiazol-2-amine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.024
4-phenyl-1,3-thiazole-2(3H)-thione
Homo sapiens
pH 6.5, 22°C
-
0.05
4-phenyl-1,3-thiazole-2-thiol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00048 - 0.048
4-phenylimidazole
0.05718
4-[(1Z)-2-[(6-bromo-1H-indazol-4-yl)amino]-N-hydroxyethanimidoyl]phenol
Homo sapiens
22°C, pH 6.5
-
0.001928
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
Homo sapiens
pH 8.0, 37°C
0.002323
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
Homo sapiens
pH 8.0, 37°C
0.0002
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzamide
Homo sapiens
pH and temperature not specified in the publication
-
0.000199 - 0.000203
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
-
0.0000836
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.000061
4-[2-(4-bromophenyl)hydrazinesulfonyl]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.038
4-[2-(methylsulfanyl)phenyl]-1H-imidazole
Homo sapiens
pH and temperature not specified in the publication
0.073
4-[3-(methylsulfanyl)phenyl]-1H-imidazole
Homo sapiens
pH and temperature not specified in the publication
0.00564
4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]phenol
Homo sapiens
22°C, pH 6.5
-
0.000256
5-(4-chlorophenyl)-3-[(2-methylpropyl)sulfanyl][1,3]thiazolo-[2,3-c][1,2,4]triazole
Homo sapiens
pH and temperature not specified in the publication
-
0.04
5-(ethylamino)quinolin-8-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.015
5-(isopropylamino)quinolin-8-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.003
5-amino-8-hydroxyquinoline
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.05
5-chloro-1,3-benzothiazole-2(3H)-thione
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.001
5-hydroxy-1,4-naphthoquinone
Homo sapiens
-
0.06
5-phenyl-1H-1,2,3-triazole
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0088
5-[(2E)-2-[(4-bromophenyl)methylidene]hydrazinyl]-1-(naphthalen-1-yl)tetrazolidine
Homo sapiens
pH 6.5, 37°C
-
0.00945
6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00109
6-bromo-N-(cyclohexylmethyl)-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.03207
6-bromo-N-[(1,4-dioxaspiro[4.5]decan-6-yl)methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.203
6-bromo-N-[(1R,2R)-2-hydroxycyclohexyl]-1H-indazole-4-carboxamide
Homo sapiens
22°C, pH 6.5
-
0.05155
6-bromo-N-[(pyridin-2-yl)methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.1049
6-bromo-N-[(pyrrolidin-3-yl)methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.0555
6-bromo-N-[[(1S,2R)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00029
6-bromo-N-[[(1S,2S)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.01736
6-bromo-N-[[(2R)-piperidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.05645
6-bromo-N-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.01375
6-bromo-N-[[(2S)-piperidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00474
6-bromo-N-[[(2S)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00019
6-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00019
6-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
Homo sapiens
pH and temperature not specified in the publication
0.00213
6-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.0031
7-hydroxy-1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
Homo sapiens
37°C, pH 6.5
-
0.00552
7-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.00302
7-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.01309
8-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolo[2,1-b]quinazoline-6,12-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00078
8-fluoro-2-[(1H-1,2,3-triazol-1-yl)methyl]indolo[2,1-b]quinazoline-6,12-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00046
8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-2-carbaldehyde
Homo sapiens
pH and temperature not specified in the publication
-
0.000534
8-fluorotryptanthrin
Homo sapiens
pH and temperature not specified in the publication
-
0.002 - 0.00205
8-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
0.000933
8-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
-
0.2
9-fluorenone
Homo sapiens
IC50 above 0.2 mM, in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00283
9-hydroxy-1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
Homo sapiens
37°C, pH 6.5
-
0.000121
9-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
Homo sapiens
alpha-caryopterone
1
9-hydroxyfluorene
Homo sapiens
IC50 above 1.0 mM, in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00292
9-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
0.000017
antisense oligonucleotide A06007H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000036
antisense oligonucleotide A06008H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000011
antisense oligonucleotide A06030H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000049
antisense oligonucleotide A06043H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000205
antisense oligonucleotide A06044H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000078
antisense oligonucleotide A06045H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000368
antisense oligonucleotide A07006H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000842
antisense oligonucleotide A07058H
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
1
benzophenone
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.07
Dichlorophene
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00001 - 0.00009
epacadostat
-
0.00019
ethyl (2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoate
Homo sapiens
pH and temperature not specified in the publication
-
0.00747
ethyl 1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl (2E)-but-2-enedioate
Homo sapiens
37°C, pH 6.5
-
0.0077
galanal
Homo sapiens
pH 6.5, 37°C, recombinant His-tagged enzyme
0.00088
gamma-glutamyl-S-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)cysteinylglycine
Homo sapiens
pH and temperature not specified in the publication
0.000097
INCB024360
Homo sapiens
pH and temperature not specified in the publication
-
0.0077
kushenol E
Homo sapiens
pH 6.5, 37°C
0.0254
kushenol F
Homo sapiens
pH 6.5, 37°C
-
0.00064
menadione
Homo sapiens
in PBS buffer (pH 7.4), at 37°C
0.00143
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylate
Homo sapiens
pH and temperature not specified in the publication
-
0.0012
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylate
Homo sapiens
pH and temperature not specified in the publication
-
0.00046
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]prolinate
Homo sapiens
pH and temperature not specified in the publication
-
0.000247
methyl 2-methyl-5,10-dioxo-5,10-dihydro-2H-benzo[g]chromene-2-carboxylate
Homo sapiens
-
0.000121
methyl 3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoate
Homo sapiens
pH and temperature not specified in the publication
0.00366
methyl 4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylate
Homo sapiens
22°C, pH 6.5
-
0.0216
methyl thiohydantoin-Trp
Homo sapiens
F5H5G0, P14902
pH 7.0, 22°C, IDO1
0.000059
N'-(3-methylphenyl)-4-[[5-(trifluoromethyl)pyridin-2-yl]oxy]benzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.000176
N'-(4-bromophenyl)-4-cyanobenzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.001431
N'-(4-bromophenyl)-4-methoxybenzene-1-sulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.000172
N'-(4-bromophenyl)benzenesulfonohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.000405
N'-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N-methyl-N-(4-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
1
N,N-dimethyl-1-[(4-phenyl-1,3-thiazol-2-yl)sulfanyl]methanamine
Homo sapiens
IC50 above 1.0 mM, in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.003
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
Homo sapiens
F5H5G0, P14902
pH 7.0, 22°C, IDO1
0.000056
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
22°C, pH 6.5
-
0.000076
N-(4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-yl)-1,1,1-trifluoromethanesulfonamide
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0029
N-(4-bromophenyl)-N'-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.044
N-(4-hydroxy-1-naphthyl)ethane-1,2-diaminium chloride
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.005
N-(4-hydroxy-1-naphthyl)propane-1,3-diaminium chloride
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.2
N-(4-hydroxynaphthalen-1-yl)pyrrolidine-2-carboxamide
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.001605
N-(4-[2-[4-(trifluoromethyl)phenyl]hydrazinesulfonyl]phenyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00161
N-(4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexylidene)hydroxylamine
Homo sapiens
22°C, pH 6.5
-
0.25
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
Homo sapiens
F5H5G0, P14902
above, pH 7.0, 22°C, IDO1
0.4
N-phenyl-p-phenylenediamine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0238
N-[(1,3-benzothiazol-2-yl)sulfanyl]-2-nitrobenzene-1-sulfonamide
Homo sapiens
pH 6.5, 37°C
-
0.1127
N-[(azetidin-3-yl)methyl]-6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00077
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]-2,2-dimethylpropanamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00136
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00208
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00351
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzenesulfonamide
Homo sapiens
pH and temperature not specified in the publication
-
0.000071
N-[4-(2-phenylhydrazinesulfonyl)phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.001
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(2-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00057
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(3-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0018
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methoxyphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.00079
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0015
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-phenylurea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0026
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(difluoromethoxy)phenyl]urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.004
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(trifluoromethoxy)phenyl]urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.000608
N-[4-[2-(2,4-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000247
N-[4-[2-(3,4-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000352
N-[4-[2-(3,5-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.001746
N-[4-[2-(3,5-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000128
N-[4-[2-(3-bromo-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000255
N-[4-[2-(3-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00011
N-[4-[2-(3-chloro-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000122
N-[4-[2-(3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00008
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]benzoyl]glycine
Homo sapiens
pH and temperature not specified in the publication
0.000049
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000205
N-[4-[2-(4-bromo-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000058
N-[4-[2-(4-bromo-3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00023
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-chlorophenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.000146
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-cyanophenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.00048
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-fluorophenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000461
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methoxyphenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000536
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.000184
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-chlorophenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000607
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methoxyphenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000703
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication
-
0.000157
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-butylurea
Homo sapiens
pH and temperature not specified in the publication
-
0.000161
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-cyclohexylurea
Homo sapiens
pH and temperature not specified in the publication
-
0.0000726
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[3-(1H-tetrazol-5-yl)phenyl]urea
Homo sapiens
pH and temperature not specified in the publication
-
0.000207
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[4-(1H-tetrazol-5-yl)phenyl]urea
Homo sapiens
pH and temperature not specified in the publication
-
0.00013
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000132
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]butanamide
Homo sapiens
pH and temperature not specified in the publication
0.000194
N-[4-[2-(4-chloro-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000155
N-[4-[2-(4-chlorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.005667
N-[4-[2-(4-cyanophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000079
N-[4-[2-(4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000254
N-[4-[2-(4-methoxyphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000051
N-[4-[2-(4-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.002475
N-[4-[2-(4-sulfamoylphenyl)hydrazinesulfonyl]phenyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000005 - 0.000097
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-2-(4-methylphenyl)acetamide
-
0.000004
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
Homo sapiens
pH and temperature not specified in the publication, cellular assay of kynurenine production
-
0.0007
N-[[(1S,2R)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00142
N-[[(1S,2S)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
Homo sapiens
22°C, pH 6.5
-
0.00008
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-4-oxobutanamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00069
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-(phenylacetyl)glycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00073
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(2-nitrophenyl)acetyl]glycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00063
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(3-nitrophenyl)acetyl]glycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00081
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(4-nitrophenyl)acetyl]glycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.00045
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-hydroxyphenyl)acetyl]-N2-methylglycinamide
Homo sapiens
pH and temperature not specified in the publication
-
0.0015
naphthalene-1,4-diol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.00099
naphthalene-1,4-dione
Homo sapiens
pH and temperature not specified in the publication
0.0235
noranhydroicaritin
Homo sapiens
pH 6.5, 37°C
0.05
primaquine
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.001202
propan-2-yl 4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoate
Homo sapiens
pH and temperature not specified in the publication
-
0.75
quinolin-8-ol
Homo sapiens
in potassium phosphate buffer (100 mM, pH 6.5) ascorbic acid (20 mM), catalase (200 units/ml), methylene blue (0.01 mM), at 37°C
0.0193
sophoraflavanone B
Homo sapiens
pH 6.5, 37°C
0.00902
tert-butyl 3-[[(6-bromo-1H-indazol-4-yl)amino]methyl]pyrrolidine-1-carboxylate
Homo sapiens
22°C, pH 6.5
-
0.00294
tert-butyl [2-(4,7-dioxo-5-phenyl-4,7-dihydro-1H-indol-3-yl)ethyl]carbamate
Homo sapiens
pH and temperature not specified in the publication
-
0.0019
tert-butyl [2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
Homo sapiens
pH and temperature not specified in the publication
-
0.00209
tert-butyl [2-[5-(2-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
Homo sapiens
pH and temperature not specified in the publication
-
0.00238
tert-butyl [2-[5-(2-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
Homo sapiens
pH and temperature not specified in the publication
-
0.001
vitamin K3
Homo sapiens
-
0.000125
[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenoxy]acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.0035
(2,4-dichlorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0012
(2-chlorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0001
(3,4-dichlorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0032
(4-chlorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
(4-chlorophenyl)methanol
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0018
(4-fluorophenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0014
(4-methoxyphenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0013
(4-methylphenyl)methanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
1-(4-chlorobenzyl)urea
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
1-(4-chlorophenyl)methanamine
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
1-(4-chlorophenyl)thiourea
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
1-[2-(4-chlorophenyl)ethyl]thiourea
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0044 - 0.013
15-deoxy-DELTA12,14-prostaglandin
2.57
1H-benzotriazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.0004
2,4-dichlorobenzyl carbamimidothioate hydrobromide
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
2-(2-chlorophenyl)ethyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
2-(3-chlorophenyl)ethyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
2-(4-chlorophenyl)ethanamine
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.057
2-(4-chlorophenyl)ethyl carbamimidothioate hydrobromide
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.25
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
Homo sapiens
F5H5G0, P14902
above, pH 7.0, 22°C, IDO2
0.01
2-chlorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.017
3,4-dichlorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.708
3-(1H-1,2,3-triazol-5-yl)pyridine
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.0046
3-chlorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-(phenylcarbonyl)benzyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-(propan-2-yl)benzyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0026
4-(trifluoromethyl)benzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0021
4-amino-N'-hydroxy-N-(3-isopropylphenyl)-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0044
4-amino-N'-hydroxy-N-(3-methoxyphenyl)-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.00055
4-amino-N'-hydroxy-N-(3-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0032
4-amino-N'-hydroxy-N-phenyl-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0065
4-amino-N-(2-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.000059
4-amino-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.000073
4-amino-N-(3-bromophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.000067
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0014
4-amino-N-(3-chlorophenyl)-1,2,5-oxadiazole-3-carbohydrazonamide
Homo sapiens
-
-
0.000086
4-amino-N-(3-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.00043
4-amino-N-(3-ethylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.0005
4-amino-N-(3-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.025
4-amino-N-(3-tert-butylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
0.006
4-amino-N-(4-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
Homo sapiens
-
-
1.028
4-bromo-5-(4-methylphenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.0013
4-bromobenzyl carbamimidothioate hydrobromide
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-chlorobenzenesulfonic acid
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0019
4-chlorobenzenethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0022
4-chlorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.021
4-chlorobenzyl N,N'-dimethylcarbamimidothioate - 1-chlorotetraoxidane (1:1)
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.019
4-cyanobenzyl carbamimidothioate hydrobromide
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.016
4-ethylbenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.013
4-fluorobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
1.371
4-iodo-5-phenyl-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.052
4-methoxybenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.03
4-methylbenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.533
4-nitro-5-(4-nitrophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.011
4-nitrobenzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-tert-butylbenzyl carbamimidothioate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
4-[(carbamimidoylsulfanyl)methyl]benzoic acid hydrochloride
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.148
5-(2-bromophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.086
5-(2-chlorophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
1.028
5-(2-methoxyphenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
1.256
5-(4-bromophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.817
5-(4-chlorophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.58
5-(4-fluorophenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
6
5-(4-methoxyphenyl)-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.143
5-phenyl-1H-1,2,3-triazole
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.061
benzyl carbamimidothioate hydrochloride
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0093
Berberine
Homo sapiens
-
pH and temperature not specified in the publication
2
ethyl 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-carboxylate
Homo sapiens
-
pH 6.5, 37°C, recombinant enzyme
0.1
methyl 4-[(carbamimidoylsulfanyl)methyl]benzenesulfinate hydrobromide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
methyl N-(4-chlorophenyl)carbamimidothioate hydroiodide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.1
methyl N-[2-(4-chlorophenyl)ethyl]carbamimidothioate hydroiodide
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.0826
methyl thiohydantoin-Trp
Homo sapiens
F5H5G0, P14902
pH 7.0, 22°C, IDO2
0.25
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
Homo sapiens
F5H5G0, P14902
above, pH 7.0, 22°C, IDO2
0.25
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
Homo sapiens
F5H5G0, P14902
above, pH 7.0, 22°C, IDO2
0.0017
phenylmethanethiol
Homo sapiens
-
in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
0.006 - 0.0095
prostaglandin (19R)-hydroxy-PGE2
0.0067 - 0.03
prostaglandin 13,14-dihydro-15-oxo-PGE2
0.0068 - 0.009
prostaglandin 15-oxo-PGE2
0.0076 - 0.0231
prostaglandin 15-oxo-PGF2alpha
0.0074 - 0.0112
prostaglandin 20-hydroxy PGE2
0.0046 - 0.0071
prostaglandin DELTA12-PGJ2
0.0049 - 0.0078
prostaglandin PGA2
0.0041 - 0.0074
prostaglandin PGD2
0.0047 - 0.0057
prostaglandin PGD2 ethanolamide
0.01 - 0.0221
prostaglandin PGE2
0.0046 - 0.0063
prostaglandin PGE2 ethanolamide
0.0071 - 0.0074
prostaglandin PGF2beta
0.0092 - 0.0112
prostaglandin PGG2
0.0072 - 0.0096
prostaglandin PGH2
0.0042 - 0.0067
prostaglandin PGJ2
0.1
sodium 4-chlorobenzenesulfinate
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH and HCl), 0.01 mM methylene blue, at 37°C
additional information
additional information
Homo sapiens
review article sumarizing data of many inhibitors of indoleamine 2,3-dioxygenase
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.000011
-
pulmonary IDO activity in pneumothorax patients
0.000014
-
pulmonary IDO activity in benign tumor patient
0.000015
-
pulmonary IDO activity in tuberculosis patient
0.000039
-
pulmonary IDO activity in bronchiectasis patient
0.00005
-
pulmonary IDO activity in lung cancer patients
0.000067
-
pulmonary IDO activity in pulmonary abscess patient
0.00033
-
crude extract of human lung slices treated with gamma-IFN
0.000598
-
supernatant, 0.8 mM L-tryptophan, 40 mM ascorbic acid, 0.02 mM methylene blue, 200 units/ml catalase, 100 mM potassium phosphate buffer, pH 6.5, 37°C, 30 min
0.022
-
sample 14 of 22 cervical mucus sampples, determined by HPLC/UV detection, reaction mixture include 0.025 mM methylene blue, 20 mM ascorbic acid, 0.04 mM L-tryptophan solution, 0.05 ml catalase and 50 mM potassium phosphate buffer (pH 6.5), 30 min, 37°C
0.024
-
sample 17 of 22 cervical mucus sampples, determined by HPLC/UV detection, reaction mixture include 0.025 mM methylene blue, 20 mM ascorbic acid, 0.04 mM L-tryptophan solution, 0.05 ml catalase and 50 mM potassium phosphate buffer (pH 6.5), 30 min, 37°C
0.072
-
assuming an average wet weight of the lens of 0.2 g, assay in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg/ml catalase, 0.4 mM L-tryptophan, 90 min, 37°C
0.474
-
sample 11 of 22 cervical mucus sampples, determined by HPLC/UV detection, reaction mixture include 0.025 mM methylene blue, 20 mM ascorbic acid, 0.04 mM L-tryptophan solution, 0.05 ml catalase and 50 mM potassium phosphate buffer (pH 6.5), 30 min, 37°C
0.479
-
sample 19 of 22 cervical mucus sampples, determined by HPLC/UV detection, reaction mixture include 0.025 mM methylene blue, 20 mM ascorbic acid, 0.04 mM L-tryptophan solution, 0.05 ml catalase and 50 mM potassium phosphate buffer (pH 6.5), 30 min, 37°C
0.636
-
sample 15 of 22 cervical mucus sampples, determined by HPLC/UV detection, reaction mixture include 0.025 mM methylene blue, 20 mM ascorbic acid, 0.04 mM L-tryptophan solution, 0.05 ml catalase and 50 mM potassium phosphate buffer (pH 6.5), 30 min, 37°C
0.689
-
sample 21 of 22 cervical mucus sampples, determined by HPLC/UV detection, reaction mixture include 0.025 mM methylene blue, 20 mM ascorbic acid, 0.04 mM L-tryptophan solution, 0.05 ml catalase and 50 mM potassium phosphate buffer (pH 6.5), 30 min, 37°C
0.913
-
sample 13 of 22 cervical mucus sampples, determined by HPLC/UV detection, reaction mixture include 0.025 mM methylene blue, 20 mM ascorbic acid, 0.04 mM L-tryptophan solution, 0.05 ml catalase and 50 mM potassium phosphate buffer (pH 6.5), 30 min, 37°C
2.48
-
kynurenine, 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid, 0.2 mg/ml catalase, 0.01 mM methylene blue, 0.4 mM tryptophan, 37°C, 10-60 min
2.58
-
-
additional information
-
0.0142 nmol/mg/lens, assay in 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg/ml catalase, 0.4 mM L-tryptophan, 90 min, 37°C
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.4
assay at
6.6 - 6.8
-
in 50 mM phosphate buffer
7.4
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5 - 7.5
pH 5.0: about 50% of maximal activity, pH 7.5: about 65% of maximal activity
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
F5H5G0, P14902
assay at room temperature
22
F5H5G0, P14902
assay at room temperature
37
-
assay at
pI VALUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.09
-
isoelectric focusing
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
detectable immunohistochemically from day 6
Manually annotated by BRENDA team
-
marrow stromal cell or mesenchymal stem cells (MSC)
Manually annotated by BRENDA team
-
from humans suffering from inflammatory neurological disorders exhibit increased IDO activity
Manually annotated by BRENDA team
-
very irregular activity
Manually annotated by BRENDA team
-
extravillous
Manually annotated by BRENDA team
-
despite suppression by progesterone, indoleamine 2,3-dioxygenase expression in endometrial stromal cells may increase during decidualization due to stimulation by interferon-gamma secreted by infiltrating leukocytes
Manually annotated by BRENDA team
-
of uterine endometrium and cervix
Manually annotated by BRENDA team
-
expression of TDO mRNA is significantly increased in the hippocampus of Alzheimer's disease patient brain. TDO co-localizes with quinolinic acid, neurofibrillary tangles-tau and amyloid deposits in the hippocampus of Alzheimer's disease patient brain
Manually annotated by BRENDA team
-
i.e. human umbilical vein endothelial cell, express little indoleamine 2,3-dioxygenase, which is poorly upregulated upon activation (except by mycoplasma)
Manually annotated by BRENDA team
-
in HUVEC cells the enzyme is upregulated by incubation with cytokines or in mycoplasma-infected cells. Inhibition of indoleamine 2,3-dioxygenase improves ability of HUVEC cells to stimulate T-cell proliferation
Manually annotated by BRENDA team
-
IDO is highly expressed throughout the intestine with a marked presence in the jejunum and ileum both at the RNA and protein level
Manually annotated by BRENDA team
-
IDO is highly expressed throughout the intestine with a marked presence in the jejunum and ileum both at the RNA and protein level
Manually annotated by BRENDA team
-
Langerhans cells possess an immunoregulatory function in promoting T cell tolerance by production of IDO
Manually annotated by BRENDA team
-
enzyme activity is detected in all lenses ranging from 26 to 80 years and there are no clear relationship of IDO activity with age
Manually annotated by BRENDA team
-
anterior and bow region
Manually annotated by BRENDA team
-
IFNgamma-primed
Manually annotated by BRENDA team
-
peritumoral infiltrate
Manually annotated by BRENDA team
low level expression
Manually annotated by BRENDA team
-
epithelium
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
additional information
-
expressed in epithelial cells but not in mature fiber cells
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug target
evolution
indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO, EC 1.13.11.11) enzymes have independently evolved to catalyze the first step in the catabolism of tryptophan (L-Trp) through the kynurenine pathway. Enzyme TDO is found in almost all metazoan and many bacterial species, but not in fungi, distribution of IDO/TDO genes among invertebrates, overview. Some lineages have independently generated multiple IDO paralogues through gene duplications. Only mammalian IDO1s and fungal typical IDOs have high affinity and catalytic efficiency for L-Trp catabolism, comparable to TDOs. Invertebrate IDO enzymes have low affinity and catalytic efficiency for L-Trp catabolism. Phylogenetic analysis. the phylogenetic distribution of low catalytic-efficiency IDOs indicates the ancestral IDO also had low affinity and catalytic efficiency for L-Trp catabolism. IDOs with high catalytic-efficiency for L-Trp catabolism may have evolved in certain lineages to fulfill particular biological roles. The low catalytic efficiency IDOs have been well conserved in a number of lineages throughout their evolution, although it is not clear that the enzymes contribute significantly to L-Trp catabolism in these species
metabolism
physiological function
drug target
conversion of tryptophan to N-formylkynurenine is the first and rate-limiting step of the tryptophan metabolic pathway (i.e., the kynurenine pathway). This conversion is catalyzed by three enzyme isoforms: indoleamine 2,3-dioxygenase 1 (IDO1), indoleamine 2,3-dioxygenase 2 (IDO2), and tryptophan-2,3-dioxygenase (TDO). As this pathway generates numerous metabolites that are involved in various pathological conditions, IDOs and TDO represent important targets for therapeutic intervention. Despite their poor sequence similarities, their active sites are highly conserved, and therefore allow the design of inhibitors with multiple activities that can target at least two isoforms
malfunction
metabolism
physiological function
additional information
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
I23O1_HUMAN
403
0
45326
Swiss-Prot
other Location (Reliability: 1)
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
190000
-
about 190000 Da in eukaryotes
320000
-
gel filtration, liver
42000
-
SDS-PAGE
43000
45000
45440
-
ESI mass spectrometry
46980
-
ESI mass spectrometry
47000
-
x * 47000, about, IDO2, SDS-PAGE
additional information
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
monomer
monomer
tetramer
additional information
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
hanging-drop vapour-diffusion method, crystal structure of the enzyme complexed with the ligand inhibitor 4-phenylimidazole and cyanide and cyanide at resolutions of 2.3 and 3.4 A respectively
-
sitting-drop vapour-diffusion method. Crystals belong to the orthorhombic space group P2(1)2(1)2, with unit-cell parameters a = 86.1, b = 98.0, c = 131.0 A. 2.3 A resolution
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
A264G
site-directed mutagenesis, mutation of a loop residues that connects the hIDO domains
A4T
variant observed in Homo sapiens
C129A
site-directed mutagenesis, the mutant shows activity similar to the wild-type enzyme
F185A
mutation eliminates activity of the enzyme
G261A
site-directed mutagenesis, mutation of a loop residues that connects the hIDO domains
G261V
site-directed mutagenesis, mutation of a loop residues that connects the hIDO domains
P182A
mutation eliminates activity of the enzyme
P182A/F185A
mutation eliminates activity of the enzyme
P314A
mutation increases IC50 for kushenol E
R213E
site-directed mutagenesis, mutation of an active site residue
R231A
site-directed mutagenesis, mutation of an active site residue involved in substrate binding
R231L
site-directed mutagenesis, altered structure compared to wild-type, inactive mutant
R77H
variant observed in Homo sapiens
R77K
variant not observed in Homo sapiens, used as control
S167A
site-directed mutagenesis, the mutant shows 3.6fold reduced activity compared to the wild-type enzyme, the mutant shows altered sensitivity to inhibitors compared to the wild-type enzyme
S167H
site-directed mutagenesis, mutation of an active site residue
S167L
site-directed mutagenesis, mutation of an active site residue
S263A
site-directed mutagenesis, mutation of a loop residues that connects the hIDO domains
T379A
D274A
-
mutant without enzyme activity, may be distal ligand or essential in maintaining the conformation of the heme pocket
F226A
-
drastically reduced the dioxygenase activity
F227A
-
drastically reduced the dioxygenase activity
H16A
-
does not act as proximal ligand
H303A
H346A
-
mutant without enzyme activity, His346 is essential for heme binding
H76A
-
active site, tryptophan binding
K352A
-
mutant with diminished heme binding ability
medicine
-
IDO expression as a T-cell inhibitory effector pathway in professional antigen-presenting cells
R231A
-
drastically reduced the dioxygenase activity
S167H
S263A
-
activity is reduced to 15%
T342A
-
site-directed mutagenesis, the mutation only slightly perturbs the global structural properties of the enzyme, but it totally abolishes the substrate stereoselectivity, substrate-free spectrum
V109A
-
mutant maintained heme binding ability
Y42F
-
active site, tryptophan binding
additional information
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
-20
-
losing 70% activity after 24 h, addition of 5 mg/ml BSA maintaines 80% activity after 5 days
4
-
maintaines 70% activity with addition of 2 mg/ml catalase for 4 days
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
the enzyme is unstable in the presence of reductants and oxygen and heme-binding ligands increase its stability
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-20°C, losing 70% activity after 24 h, addition of 5 mg/ml bovine serum albumin maintains 80% activity after 5 days
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
HisTrap column chromatography and Superdex 200 gel filtration
IMAC nickel affinity column chromatography
recombinant His-tagged enzyme from Escherichia coli strain BL21 Star (DE3) by two steps of nickel affinity chromatography and dialysis
recombinant His-tagged enzyme from Escherichia coli strain BL21(DE3) by nickel affinity chromatography and gel filtration
recombinant His-tagged IDO1 from Escherichia coli strain BL21(DE3) by nickel affinity chromatography and gel filtration
recombinant His6-tagged IDO1 from Escherichia coli strain BL21 Star by nickel affinity chromatography and gel filtration
F5H5G0, P14902
0-5°C, homogenization, Protein G-Sepharose
-
cryosections deparaffinized, rehydrated, cooked in 0.01 M citrate buffer (pH 6.0), incubated with IDO antibody at room temperature for 30 min
-
homogenization, filtered through cotton gauze, centrifugation, collection, stored at -20°C
-
Ni-NTA-agarose and gel filtration (Superdex 75)
-
phosphocellulose and Ni-NTA-agarose affinity chromatography
-
recombinant
-
recombinant enzyme
recombinant enzyme from Escherichia coli involving affinity chromatography
-
recombinant enzyme, fusion protein to a hexahistidyl tag
-
recombinant His-tagged IDO2 from Escherichia coli strain BL21(DE3) by nickel affinity chromatography and gel filtration
recombinant His6-tagged IDO2 from Escherichia coli strain BL21 Star by nickel affinity chromatography and gel filtration
F5H5G0, P14902
the use of ALA, the biosynthetic precursor of protoporphyrin IX, coupled with metal-affinity chromatography and size exclusion chromatography produces 6His-IDP with a protein to heme ratio of 1:2.2
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in COS-7 and HEK293 cell, C-terminal hemagglutinin-tagged
expressed in Escherichia coli BL21 AI cells
expressed in Escherichia coli BL21 Star cells
expression in Escherichia coli
expression in Escherichia coli BL21(DE3)
expression of His6-tagged IDO1 in Escherichia coli strain BL21 Star
F5H5G0, P14902
gene IDO1, DNA and amino acid sequence determination and analysis, sequence and genetic structure comparisons, and phylogenetic analysis, recombinant expression of His6-tagged enzyme in Escherichia coli strain KRX. No complementation of the enzyme-deficient Saccharomyces cerevisiae
gene IDO1, recombinant expression His-tagged enzyme in Escherichia coli strain BL21(DE3)
gene IDO1, recombinant expression of His-tagged enzyme in Escherichia coli strain BL21 Star (DE3), real-time PCR enzyme expression analysis
gene IDO1, recombinant expression of His-tagged enzyme in Escherichia coli strain BL21(DE3)
gene IDO1, semi-quantitative RT-PCR and quantitative real-time RT-PCR enzyme expression analysis in lipopolysaccgaride-stimulated THP-1 cells, recombinant expression of N-terminally His-tagged enzyme in Escherichia coli
large scale expression in Escherichia coli
recombinant overexpression of enzyme IDO in HEK-293 cells
C-terminal hexahistidine tag, expressed in Escherichia coli
-
construction of recombinant replication-defective adenoviruses harboring the human indoleamine 2,3-dioxygenase gene and expression in dendritic cells
-
COS-7 cells expressing active human IDO
-
expressed in Escherichia coli
-
expressed in HeLa cells
-
expressed in Mus musculus
-
expression in Escherichia coli
expression in Escherichia coli as a full-length, C-terminal hexahistidine fusion protein
expression in Escherichia coli E538, expressed with His-Tag
-
expression in Escherichia coli E538, formation of inclusion bodies at 37°C with reduced formation, at 30°C, expressed with His-Tag
-
expression in Escherichia coli EC538 as a fusion protein to a hexahistidyl tag
-
expression in Escherichia coli strain YA21
-
expression in Saccharomyces cerevisiae tryptophan auxotroph can restore growth in presence of low tryptophan concentrations
-
expression of His-tagged enzyme in Escherichia coli, optimised expression
-
expression of His6-tagged IDO2 in Escherichia coli strain BL21 Star
F5H5G0, P14902
gene IDO2, recombinant expression of His-tagged enzyme in Escherichia coli strain BL21(DE3)
hexa-histidine tag, expressed in Escherichia coli
-
N-terminal His tag, expressed in Escherichia coli
-
quantitative real-time RT PCR enzyme expression analysis
-
recombinant expression in Escherichia coli
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
IDO expression is not induced by interferon-alpha
IDO is an interferon-gamma-induced enzyme
IFN-gamma stimulates the expression of indoleamine 2,3-dioxygenase
suppressive effect of plant extracts or phytochemicals on IDO1 induction and activity
the enzyme is cytokine-inducible
the methanol extracts of Myoga flower buds, which are traditional Japanese foods, and labdane-type diterpene galanal derived from Myoga flowers significantly suppress IDO1 activity
treated with interferon gamma stimulates hIDO1 expression
arachinoate and the prostaglandin metabolite, PGD2, repress the IFNgamma mediated activity of IDO-1 in THP-1 cells and human monocytes
-
IDO activity is increased during severe sepsis and septic shock and is associated with mortality. IDO activity is maximal in culture after 3 days of interferon-gamma stimulation
-
IDO expression is induced by interferon-gamma. IDO is detected when exposed to 100 units/ml IFN-gamma for 4 h and is enhanced by continuous exposure to IFN-gamma
-
IDO expression is negatively regulated by interleukin-4, nitric oxide and transforming growth factor-beta
-
IDO expression is positively regulated by interferon-gamma, CD40 ligand, COX-2, lipopolysaccharide, tumor necrosis factor-alpha, and hepatocyte growth factor
-
IDO-1 levels are increased in Alzheimer's disease brains compared to controls
-
IDO1 expression is upregulated by cytokines such as IFN-gamma, e.g. in HELA cells, IDO2 mRNA expression is upregulated in response to IFN-gamma in some cancer cell lines as well and human mesenchymal stem cells
-
interferon-gamma induces the expression of indoleamine 2,3-dioxygenase, an 100fold and 200fold increase in IDO activity is detected with IFN-gamma concentrations of 5 and 10 units/ml, respectively
-
sodium butyrate down-regulates indoleamine 2,3-dioxygenase at the transcriptional and post-transcriptional levels. Treatment with sodium butyrate (up to 0.2 mM) significantly reduces IDO induction, which is almost completely inhibited at a concentration of 0.5 mM. Sodium butyrate causes a ubiquitin-mediated proteasomal degradation process that contributes to degradation of IDO. Treatment with bortezomib significantly represses sodium butyrate-induced down-regulation of IDO protein
-
TLR9 ligand CpG, soluble CTLA4 or interferon-gamma induce IDO expression
-
treatment with 1000 units/ml interferon-gamma increases the PDL-1 cell surface expression and the IDO activity
-
treatment with 25 ng HIV-1 clade B Tat protein significantly upregulates IDO gene and protein expression 24 h after incubation compared to HIV-1 clade C Tat protein
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
medicine
identification of genetic variants, which have altered enzyme activity
drug development
-
the enzyme is a promising therapeutic target of cancer
medicine
pharmacology
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Badawy, A.A.
Central role of tryptophan pyrrolase in haem metabolism
Biochem. Soc. Trans.
7
575-583
1979
Bos taurus, Cavia porcellus, Gallus gallus, Oryctolagus cuniculus, Felis catus, Frog, Meriones unguiculatus, Cricetinae, Ovis aries, Homo sapiens, Meleagris gallopavo, Mus musculus, Rattus norvegicus, Sus scrofa
Manually annotated by BRENDA team
Littlejohn, T.K.; Takikawa, O.; Skylas, D.; Jamie, J.F.; Walker, M.J.; Truscott, R.J.W.
Expression and purification of recombinant human indoleamine 2,3-dioxygenase
Protein Expr. Purif.
19
22-29
2000
Homo sapiens
Manually annotated by BRENDA team
Thomas, S.R.; Mohr, D.; Stocker, R.
Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes
J. Biol. Chem.
269
14457-14464
1994
Homo sapiens
Manually annotated by BRENDA team
Hissong, B.D.; Byrne, G.I.; Padilla, M.L.; Carlin, J.M.
Upregulation of interferon-induced indoleamine 2,3-dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl tripeptide, and interleukin-1
Cell. Immunol.
160
264-269
1995
Homo sapiens
Manually annotated by BRENDA team
Takikawa, O.; Littlejohn, T.K.; Truscott, R.J.W.
Indoleamine 2,3-dioxygenase in the human lens, the first enzyme in the synthesis of UV filters
Exp. Eye Res.
72
271-277
2001
Homo sapiens
Manually annotated by BRENDA team
Kudo, Y.; Boyd, C.A.R.; Sargent, I.L.; Redman, C.W.G.
Tryptophan degradation by human placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation
J. Physiol.
535
207-215
2001
Homo sapiens
Manually annotated by BRENDA team
Kudo, Y.; Boyd, C.A.R.
Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection
Biochim. Biophys. Acta
1500
119-124
2000
Homo sapiens
Manually annotated by BRENDA team
Musso, T.; Gusella, G.L.; Brooks, A.; Longo, D.L.; Varesio, L.
Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes
Blood
83
1408-1411
1994
Homo sapiens
Manually annotated by BRENDA team
Terentis, A.C.; Thomas, S.R.; Takikawa, O.; Littlejohn, T.K.; Truscott, R.J.W.; Armstrong, R.S.; Yeh, S.R.; Stocker, R.
The heme environment of recombinant human indoleamine 2,3-dioxygenase: Structural properties and substrate-ligand interactions
J. Biol. Chem.
277
15788-15794
2002
Homo sapiens
Manually annotated by BRENDA team
Terness, P.; Bauer, T.M.; Rose, L.; Dufter, C.; Watzlik, A.; Simon, H.; Opelz, G.
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites
J. Exp. Med.
196
447-457
2002
Homo sapiens
Manually annotated by BRENDA team
Comings, D.E.; Muhleman, D.; Dietz, G.; Sherman, M.; Forest, G.L.
Sequence of human tryptophan 2,3-dioxygenase (TDO2): presence of a glucocorticoid response-like element composed of a GTT repeat and an intronic CCCCT repeat
Genomics
29
390-396
1995
Homo sapiens (P48775)
Manually annotated by BRENDA team
Kadoya, A.; Tone, S.; Mareda, H.; Minatogawa, Y.; Kido, R.
Gene structure of human indoleamine 2,3-dioxygenase
Biochem. Biophys. Res. Commun.
189
530-536
1992
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Dai, W.; Gupta, S.L.
Molecular cloning, sequencing and expression of human interferon-gamma-inducible indoleamine 2,3-dioxygenase cDNA
Biochem. Biophys. Res. Commun.
168
1-8
1990
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Tone, S.; Takikawa, O.; Habara-Ohkubo, A.; Kadoxa, A.; Yoshida, R.; Kido, R.
Primary structure of human indoleamine 2,3-dioxygenase deduced from the nucleotide sequence of its cDNA
Nucleic Acids Res.
18
367
1990
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Kwidzinski, E.; Bunse, J.; Kovac, A.D.; Ullrich, O.; Zipp, F.; Nitsch, R.; Bechmann, I.
IDO (indolamine 2,3-dioxygenase) expression and function in the CNS
Adv. Exp. Med. Biol.
527
113-118
2003
Homo sapiens
Manually annotated by BRENDA team
Takikawa, O.; Truscott, R.J.; Fukao, M.; Miwa, S.
Age-related nuclear cataract and indoleamine 2,3-dioxygenase-initiated tryptophan metabolism in the human lens
Adv. Exp. Med. Biol.
527
277-285
2003
Homo sapiens
Manually annotated by BRENDA team
Sedlmayr, P.; Semlitsch, M.; Gebru, G.; Karpf, E.; Reich, O.; Tang, T.; Wintersteiger, R.; Takikawa, O.; Dohr, G.
Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix
Adv. Exp. Med. Biol.
527
91-95
2003
Homo sapiens
Manually annotated by BRENDA team
Ferry, G.; Ubeaud, C.; Lambert, P.H.; Bertin, S.; Coge, F.; Chomarat, P.; Delagrange, P.; Serkiz, B.; Bouchet, J.P.; Truscott, R.J.W.; Boutin, J.A.
Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase
Biochem. J.
388
205-215
2005
Homo sapiens (P48775)
Manually annotated by BRENDA team
Kudo, Y.; Hara, T.; Katsuki, T.; Toyofuku, A.; Katsura, Y.; Takikawa, O.; Fujii, T.; Ohama, K.
Mechanisms regulating the expression of indoleamine 2,3-dioxygenase during decidualization of human endometrium
Hum. Reprod.
19
1222-1230
2004
Homo sapiens
Manually annotated by BRENDA team
Littlejohn, T.K.; Takikawa, O.; Jamie, J.F.; Walker, M.J.; Truscott, R.J.W.
Production of truncated enzymically active human indoleamine 2,3-dioxygenase using site-directed mutagenesis
Int. Congr. Ser.
1233
157-160
2002
Homo sapiens
-
Manually annotated by BRENDA team
Littlejohn, T.K.; Takikawa, O.; Truscott, R.J.W.; Walker, M.J.
Asp274 and His346 are essential for heme binding and catalytic function of human indolamine 2,3-dioxygenase
J. Biol. Chem.
278
29525-29531
2003
Homo sapiens
Manually annotated by BRENDA team
von Bubnoff, D.; Bausinger, H.; Matz, H.; Koch, S.; Hacker, G.; Takikawa, O.; Bieber, T.; Hanau, D.; de la Salle, H.
Human epidermal langerhans cells express the immunoregulatory enzyme indoleamine 2,3-dioxygenase
J. Invest. Dermatol.
123
298-304
2004
Homo sapiens
Manually annotated by BRENDA team
Kudo, Y.; Boyd, C.A.; Spyropoulou, I.; Redman, C.W.; Takikawa, O.; Katsuki, T.; Hara, T.; Ohama, K.; Sargent, I.L.
Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta
J. Reprod. Immunol.
61
87-98
2004
Homo sapiens
Manually annotated by BRENDA team
Ligam, P.; Manuelpillai, U.; Wallace, E.M.; Walker, D.
Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy
Placenta
26
498-504
2005
Homo sapiens
Manually annotated by BRENDA team
Austin, C.J.; Mizdrak, J.; Matin, A.; Sirijovski, N.; Kosim-Satyaputra, P.; Willows, R.D.; Roberts, T.H.; Truscott, R.J.; Polekhina, G.; Parker, M.W.; Jamie, J.F.
Optimised expression and purification of recombinant human indoleamine 2,3-dioxygenase
Protein Expr. Purif.
37
392-398
2004
Homo sapiens
Manually annotated by BRENDA team
Kai, S.; Goto, S.; Tahara, K.; Sasaki, A.; Tone, S.; Kitano, S.
Indolamine 2,3-dioxygenase is necessary for cytolytic activity of natural killer cells
Scand. J. Immunol.
59
177-182
2004
Homo sapiens
Manually annotated by BRENDA team
Watanabe, Y.; Fujiwara, M.; Yoshida, R.; Hayaishi, O.
Stereospecificity of hepatic L-tryptophan 2,3-dioxygenase
Biochem. J.
189
393-405
1980
Bos taurus, Capra hircus, Oryctolagus cuniculus, Homo sapiens, Macaca fuscata fuscata, Mus musculus, Pseudomonas fluorescens, Rattus norvegicus, Sus scrofa
Manually annotated by BRENDA team
Meisel, R.; Zibert, A.; Laryea, M.; Gobel, U.; Daubener, W.; Dilloo, D.
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation
Blood
103
4619-4621
2004
Homo sapiens
Manually annotated by BRENDA team
Daubener, W.; Spors, B.; Hucke, C.; Adam, R.; Stins, M.; Kim, K.S.; Schroten, H.
Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase
Infect. Immun.
69
6527-6531
2001
Homo sapiens
Manually annotated by BRENDA team
Southan, M.D.; Truscott, R.J.W.; Jamie, J.F.; Pelosi, L.; Walker, M.J.; Maeda, H.; Iwamoto, Y.; Tone, S.
Structural requirements of the competitive binding site of recombinant human indoleamine 2,3-dioxygenase
Med. Chem. Res.
6
343-352
1996
Homo sapiens
-
Manually annotated by BRENDA team
Sedlmayr, P.; Blaschitz, A.; Wintersteiger, R.; Semlitsch, M.; Hammer, A.; MacKenzie, C.R.; Walcher, W.; Reich, O.; Takikawa, O.; Dohr, G.
Localization of indoleamine 2,3-dioxygenase in human female reproductive organs and the placenta
Mol. Hum. Reprod.
8
385-391
2002
Homo sapiens
Manually annotated by BRENDA team
Yasui, H.; Takai, K.; Yoshida, R.; Hayaishi, O.
Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients
Proc. Natl. Acad. Sci. USA
83
6622-6626
1986
Homo sapiens
Manually annotated by BRENDA team
Thomas, S.R.; Stocker, R.
Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway
Redox Rep.
4
199-220
1999
Oryctolagus cuniculus, Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Oda, S.; Sugimoto, H.; Yoshida, T.; Shiro, Y.
Crystallization and preliminary crystallographic studies of human indoleamine 2,3-dioxygenase
Acta Crystallogr. Sect. F
62
221-223
2006
Homo sapiens
Manually annotated by BRENDA team
Beutelspacher, S.C.; Tan, P.H.; McClure, M.O.; Larkin, D.F.; Lechler, R.I.; George, A.J.
Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses
Am. J. Transplant.
6
1320-1330
2006
Homo sapiens
Manually annotated by BRENDA team
Takikawa, O.
Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism
Biochem. Biophys. Res. Commun.
338
12-19
2005
Oryctolagus cuniculus, Homo sapiens
Manually annotated by BRENDA team
Papadopoulou, N.D.; Mewies, M.; McLean, K.J.; Seward, H.E.; Svistunenko, D.A.; Munro, A.W.; Raven, E.L.
Redox and spectroscopic properties of human indoleamine 2,3-dioxygenase and a His303Ala variant: implications for catalysis
Biochemistry
44
14318-14328
2005
Homo sapiens
Manually annotated by BRENDA team
Samelson-Jones, B.J.; Yeh, S.R.
Interactions between nitric oxide and indoleamine 2,3-dioxygenase
Biochemistry
45
8527-8538
2006
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Vottero, E.; Balgi, A.; Woods, K.; Tugendreich, S.; Melese, T.; Andersen, R.J.; Mauk, A.G.; Roberge, M.
Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast
Biotechnol. J.
1
282-288
2006
Homo sapiens
Manually annotated by BRENDA team
von Bergwelt-Baildon, M.S.; Popov, A.; Saric, T.; Chemnitz, J.; Classen, S.; Stoffel, M.S.; Fiore, F.; Roth, U.; Beyer, M.; Debey, S.; Wickenhauser, C.; Hanisch, F.G.; Schultze, J.L.
CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition
Blood
108
228-237
2006
Homo sapiens
Manually annotated by BRENDA team
Brastianos, H.C.; Vottero, E.; Patrick, B.O.; Van Soest, R.; Matainaho, T.; Mauk, A.G.; Andersen, R.J.
Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua
J. Am. Chem. Soc.
128
16046-16047
2006
Homo sapiens
Manually annotated by BRENDA team
Pereira, A.; Vottero, E.; Roberge, M.; Mauk, A.G.; Andersen, R.J.
Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata
J. Nat. Prod.
69
1496-1499
2006
Homo sapiens
Manually annotated by BRENDA team
Sugimoto, H.; Oda, S.; Otsuki, T.; Hino, T.; Yoshida, T.; Shiro, Y.
Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase
Proc. Natl. Acad. Sci. USA
103
2611-2616
2006
Homo sapiens
Manually annotated by BRENDA team
Austin, C.J.; Astelbauer, F.; Kosim-Satyaputra, P.; Ball, H.J.; Willows, R.D.; Jamie, J.F.; Hunt, N.H.
Mouse and human indoleamine 2,3-dioxygenase display some distinct biochemical and structural properties
Amino Acids
36
99-106
2009
Mus musculus, Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Basran, J.; Rafice, S.A.; Chauhan, N.; Efimov, I.; Cheesman, M.R.; Ghamsari, L.; Raven, E.L.
A kinetic, spectroscopic, and redox study of human tryptophan 2,3-dioxygenase
Biochemistry
47
4752-4760
2008
Homo sapiens, Homo sapiens (P48775)
Manually annotated by BRENDA team
Chauhan, N.; Basran, J.; Efimov, I.; Svistunenko, D.A.; Seward, H.E.; Moody, P.C.; Raven, E.L.
The role of serine 167 in human indoleamine 2,3-dioxygenase: a comparison with tryptophan 2,3-dioxygenase
Biochemistry
47
4761-4769
2008
Homo sapiens, Xanthomonas campestris
Manually annotated by BRENDA team
Macchiarulo, A.; Nuti, R.; Bellocchi, D.; Camaioni, E.; Pellicciari, R.
Molecular docking and spatial coarse graining simulations as tools to investigate substrate recognition, enhancer binding and conformational transitions in indoleamine-2,3-dioxygenase (IDO)
Biochim. Biophys. Acta
1774
1058-1068
2007
Homo sapiens (P14902)
Manually annotated by BRENDA team
Metz, R.; Duhadaway, J.B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A.J.; Prendergast, G.C.
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
Cancer Res.
67
7082-7087
2007
Homo sapiens
Manually annotated by BRENDA team
Pertovaara, M.; Raitala, A.; Juonala, M.; Lehtimaeki, T.; Huhtala, H.; Oja, S.S.; Jokinen, E.; Viikari, J.S.; Raitakari, O.T.; Hurme, M.
Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the cardiovascular risk in young Finns study
Clin. Exp. Immunol.
148
106-111
2007
Homo sapiens
Manually annotated by BRENDA team
Torres, M.I.; Lopez-Casado, M.A.; Lorite, P.; Rios, A.
Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease
Clin. Exp. Immunol.
148
419-424
2007
Homo sapiens
Manually annotated by BRENDA team
Werner, E.R.; Werner-Felmayer, G.
Substrate and cofactor requirements of indoleamine 2,3-dioxygenase in interferon-gamma-treated cells: utilization of oxygen rather than superoxide
Curr. Drug Metab.
8
201-203
2007
Homo sapiens
Manually annotated by BRENDA team
Ball, H.J.; Sanchez-Perez, A.; Weiser, S.; Austin, C.J.; Astelbauer, F.; Miu, J.; McQuillan, J.A.; Stocker, R.; Jermiin, L.S.; Hunt, N.H.
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice
Gene
396
203-213
2007
Homo sapiens (Q6ZQW0), Homo sapiens, Mus musculus (Q8R0V5), Mus musculus
Manually annotated by BRENDA team
King, N.J.; Thomas, S.R.
Molecules in focus: indoleamine 2,3-dioxygenase
Int. J. Biochem. Cell Biol.
39
2167-2172
2007
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Batabyal, D.; Yeh, S.R.
Human tryptophan dioxygenase: a comparison to indoleamine 2,3-dioxygenase
J. Am. Chem. Soc.
129
15690-15701
2007
Homo sapiens
Manually annotated by BRENDA team
Chung, L.W.; Li, X.; Sugimoto, H.; Shiro, Y.; Morokuma, K.
Density functional theory study on a missing piece in understanding of heme chemistry: the reaction mechanism for indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase
J. Am. Chem. Soc.
130
12299-12309
2008
Homo sapiens
Manually annotated by BRENDA team
Thomas, S.R.; Terentis, A.C.; Cai, H.; Takikawa, O.; Levina, A.; Lay, P.A.; Freewan, M.; Stocker, R.
Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide
J. Biol. Chem.
282
23778-23787
2007
Homo sapiens
Manually annotated by BRENDA team
Yuasa, H.J.; Takubo, M.; Takahashi, A.; Hasegawa, T.; Noma, H.; Suzuki, T.
Evolution of vertebrate indoleamine 2,3-dioxygenases
J. Mol. Evol.
65
705-714
2007
Homo sapiens (P14902), Mus musculus (P28776), Mus musculus, Rattus norvegicus (Q9ERD9)
Manually annotated by BRENDA team
Larrea, E.; Riezu-Boj, J.I.; Gil-Guerrero, L.; Casares, N.; Aldabe, R.; Sarobe, P.; Civeira, M.P.; Heeney, J.L.; Rollier, C.; Verstrepen, B.; Wakita, T.; Borras-Cuesta, F.; Lasarte, J.J.; Prieto, J.
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection
J. Virol.
81
3662-3666
2007
Homo sapiens, Pan troglodytes
Manually annotated by BRENDA team
Corm, S.; Berthon, C.; Imbenotte, M.; Biggio, V.; Lhermitte, M.; Dupont, C.; Briche, I.; Quesnel, B.
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients sera by HPLC and is inducible by IFN-gamma
Leuk. Res.
33
490-494
2009
Homo sapiens
Manually annotated by BRENDA team
Macchiarulo, A.; Camaioni, E.; Nuti, R.; Pellicciari, R.
Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease
Amino Acids
37
219-229
2009
Mus musculus, Homo sapiens (P14902)
Manually annotated by BRENDA team
Rafice, S.A.; Chauhan, N.; Efimov, I.; Basran, J.; Raven, E.L.
Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase
Biochem. Soc. Trans.
37
408-412
2009
Saccharomyces cerevisiae, Oryctolagus cuniculus, Drosophila melanogaster, Homo sapiens, Mus musculus, Cupriavidus metallidurans, Xanthomonas campestris
Manually annotated by BRENDA team
Nakashima, H.; Uto, Y.; Nakata, E.; Nagasawa, H.; Ikkyu, K.; Hiraoka, N.; Nakashima, K.; Sasaki, Y.; Sugimoto, H.; Shiro, Y.; Hashimoto, T.; Okamoto, Y.; Asakawa, Y.; Hori, H.
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors
Bioorg. Med. Chem.
16
8661-8669
2008
Homo sapiens
Manually annotated by BRENDA team
Curti, A.; Trabanelli, S.; Salvestrini, V.; Baccarani, M.; Lemoli, R.M.
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood
113
2394-2401
2009
Homo sapiens
Manually annotated by BRENDA team
Clarke, G.; Fitzgerald, P.; Cryan, J.F.; Cassidy, E.M.; Quigley, E.M.; Dinan, T.G.
Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort
BMC Gastroenterol.
9
6
2009
Homo sapiens
Manually annotated by BRENDA team
Qian, F.; Villella, J.; Wallace, P.K.; Mhawech-Fauceglia, P.; Tario, J.D.; Andrews, C.; Matsuzaki, J.; Valmori, D.; Ayyoub, M.; Frederick, P.J.; Beck, A.; Liao, J.; Cheney, R.; Moysich, K.; Lele, S.; Shrikant, P.; Old, L.J.; Odunsi, K.
Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer
Cancer Res.
69
5498-5504
2009
Homo sapiens
Manually annotated by BRENDA team
Schmidt, S.K.; Mueller, A.; Heseler, K.; Woite, C.; Spekker, K.; MacKenzie, C.R.; Daeubener, W.
Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase
Eur. J. Immunol.
39
2755-2764
2009
Homo sapiens
Manually annotated by BRENDA team
Quan, J.; Tan, P.H.; MacDonald, A.; Friend, P.J.
Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges
Expert. Opin. Biol. Ther.
8
1705-1719
2008
Homo sapiens
Manually annotated by BRENDA team
Spekker, K.; Czesla, M.; Ince, V.; Heseler, K.; Schmidt, S.K.; Schares, G.; Daeubener, W.
Indoleamine 2,3-dioxygenase is involved in defense against Neospora caninum in human and bovine cells
Infect. Immun.
77
4496-4501
2009
Bos taurus, Homo sapiens
Manually annotated by BRENDA team
Cherayil, B.J.
Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation
Inflamm. Bowel Dis.
15
1391-1396
2009
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Lu, C.; Lin, Y.; Yeh, S.R.
Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase
J. Am. Chem. Soc.
131
12866-12867
2009
Homo sapiens
Manually annotated by BRENDA team
Fukumura, E.; Sugimoto, H.; Misumi, Y.; Ogura, T.; Shiro, Y.
Cooperative binding of L-trp to human tryptophan 2,3-dioxygenase: resonance Raman spectroscopic analysis
J. Biochem.
145
505-515
2009
Homo sapiens
Manually annotated by BRENDA team
Nickel, E.; Nienhaus, K.; Lu, C.; Yeh, S.R.; Nienhaus, G.U.
Ligand and substrate migration in human indoleamine 2,3-dioxygenase
J. Biol. Chem.
284
31548-31554
2009
Homo sapiens
Manually annotated by BRENDA team
Mueller, A.; Heseler, K.; Schmidt, S.K.; Spekker, K.; Mackenzie, C.R.; Daeubener, W.
The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects
J. Cell. Mol. Med.
13
1125-1135
2008
Homo sapiens
Manually annotated by BRENDA team
Becerra, A.; Warke, R.V.; Xhaja, K.; Evans, B.; Evans, J.; Martin, K.; de Bosch, N.; Rothman, A.L.; Bosch, I.
Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function
J. Gen. Virol.
90
810-817
2009
Homo sapiens
Manually annotated by BRENDA team
Chen, W.; Liang, X.; Peterson, A.J.; Munn, D.H.; Blazar, B.R.
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation
J. Immunol.
181
5396-5404
2008
Homo sapiens
Manually annotated by BRENDA team
Kumar, S.; Malachowski, W.P.; DuHadaway, J.B.; LaLonde, J.M.; Carroll, P.J.; Jaller, D.; Metz, R.; Prendergast, G.C.; Muller, A.J.
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors
J. Med. Chem.
51
1706-1718
2008
Homo sapiens (P14902)
Manually annotated by BRENDA team
Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J.M.; DuHadaway, J.B.; Malachowski, W.P.; Prendergast, G.C.; Muller, A.J.
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase
J. Med. Chem.
51
4968-4977
2008
Homo sapiens (P14902)
Manually annotated by BRENDA team
Yue, E.W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K.J.; Hansbury, M.J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T.C.; Koblish, H.K.; Fridman, J.S.; Metcalf, B.; Scherle, P.A.; Combs, A.P.
Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model
J. Med. Chem.
52
7364-7367
2009
Homo sapiens
Manually annotated by BRENDA team
Mailankot, M.; Staniszewska, M.M.; Butler, H.; Caprara, M.H.; Howell, S.; Wang, B.; Doller, C.; Reneker, L.W.; Nagaraj, R.H.
Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lens
Lab. Invest.
89
498-512
2009
Homo sapiens
Manually annotated by BRENDA team
Hoshi, M.; Ito, H.; Fujigaki, H.; Takemura, M.; Takahashi, T.; Tomita, E.; Ohyama, M.; Tanaka, R.; Saito, K.; Seishima, M.
Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity
Leuk. Res.
33
39-45
2009
Homo sapiens
Manually annotated by BRENDA team
Zelante, T.; Fallarino, F.; Bistoni, F.; Puccetti, P.; Romani, L.
Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host
Microbes Infect.
11
133-141
2009
Homo sapiens
Manually annotated by BRENDA team
Schefold, J.C.; Zeden, J.P.; Fotopoulou, C.; von Haehling, S.; Pschowski, R.; Hasper, D.; Volk, H.D.; Schuett, C.; Reinke, P.
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms
Nephrol. Dial. Transplant.
24
1901-1908
2009
Homo sapiens
Manually annotated by BRENDA team
Arefayene, M.; Philips, S.; Cao, D.; Mamidipalli, S.; Desta, Z.; Flockhart, D.A.; Wilkes, D.S.; Skaar, T.C.
Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity
Pharmacogenet. Genomics
19
464-476
2009
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Huttunen, R.; Syrjaenen, J.; Aittoniemi, J.; Oja, S.S.; Raitala, A.; Laine, J.; Pertovaara, M.; Vuento, R.; Huhtala, H.; Hurme, M.
High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients
Shock
33
149-154
2010
Homo sapiens
Manually annotated by BRENDA team
Liu, J.; Lu, G.; Tang, F.; Liu, Y.; Cui, G.
Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas
Virchows Arch.
455
441-448
2009
Homo sapiens
Manually annotated by BRENDA team
Nishizawa, H.; Kato, T.; Ota, S.; Nishiyama, S.; Pryor-Koishi, K.; Suzuki, M.; Tsutsumi, M.; Inagaki, H.; Kurahashi, H.; Udagawa, Y.
Genetic variation in the indoleamine 2,3-dioxygenase gene in pre-eclampsia
Am. J. Reprod. Immunol.
64
68-76
2010
Homo sapiens
Manually annotated by BRENDA team
Yanagisawa, S.; Sugimoto, H.; Shiro, Y.; Ogura, T.
A specific interaction of L-tryptophan with CO of CO-bound indoleamine 2,3-dioxygenase identified by resonance Raman spectroscopy
Biochemistry
49
10081-10088
2010
Homo sapiens
Manually annotated by BRENDA team
Pearson, J.T.; Siu, S.; Meininger, D.P.; Wienkers, L.C.; Rock, D.A.
In vitro modulation of cytochrome P450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b5 and methylene blue
Biochemistry
49
2647-2656
2010
Homo sapiens (P14902)
Manually annotated by BRENDA team
Lu, C.; Lin, Y.; Yeh, S.R.
Spectroscopic studies of ligand and substrate binding to human indoleamine 2,3-dioxygenase
Biochemistry
49
5028-5034
2010
Homo sapiens
Manually annotated by BRENDA team
Matsuno, K.; Takai, K.; Isaka, Y.; Unno, Y.; Sato, M.; Takikawa, O.; Asai, A.
S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase
Bioorg. Med. Chem. Lett.
20
5126-5129
2010
Homo sapiens
Manually annotated by BRENDA team
Soerensen, R.B.; Hadrup, S.R.; Svane, I.M.; Hjortso, M.C.; Thor Straten, P.; Andersen, M.H.
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Blood
117
2200-2210
2011
Homo sapiens
Manually annotated by BRENDA team
Juergens, B.; Fuchs, D.; Reichenbach, J.; Heitger, A.
Intact indoleamine 2,3-dioxygenase activity in human chronic granulomatous disease
Clin. Immunol.
137
1-4
2010
Homo sapiens
Manually annotated by BRENDA team
John, S.; Thangapandian, S.; Sakkiah, S.; Lee, K.W.
Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies
Eur. J. Med. Chem.
45
4004-4012
2010
Homo sapiens (P14902)
Manually annotated by BRENDA team
Di Pucchio, T.; Danese, S.; De Cristofaro, R.; Rutella, S.
Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds
Expert Opin. Ther. Pat.
20
229-250
2010
Homo sapiens
Manually annotated by BRENDA team
Matteoli, G.; Mazzini, E.; Iliev, I.D.; Mileti, E.; Fallarino, F.; Puccetti, P.; Chieppa, M.; Rescigno, M.
Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction
Gut
59
595-604
2010
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Mailankot, M.; Nagaraj, R.H.
Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human lens epithelial cells: apoptosis through the formation of 3-hydroxykynurenine
Int. J. Biochem. Cell Biol.
42
1446-1454
2010
Homo sapiens
Manually annotated by BRENDA team
Jiang, G.M.; He, Y.W.; Fang, R.; Zhang, G.; Zeng, J.; Yi, Y.M.; Zhang, S.; Bu, X.Z.; Cai, S.H.; Du, J.
Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels
Int. J. Biochem. Cell Biol.
42
1840-1846
2010
Homo sapiens
Manually annotated by BRENDA team
Yu, C.J.; Zheng, M.F.; Kuang, C.X.; Huang, W.D.; Yang, Q.
Oren-gedoku-to and its constituents with therapeutic potential in Alzheimers disease inhibit indoleamine 2, 3-dioxygenase activity in vitro
J. Alzheimers Dis.
22
257-266
2010
Homo sapiens
Manually annotated by BRENDA team
Davydov, R.M.; Chauhan, N.; Thackray, S.J.; Anderson, J.L.; Papadopoulou, N.D.; Mowat, C.G.; Chapman, S.K.; Raven, E.L.; Hoffman, B.M.
Probing the ternary complexes of indoleamine and tryptophan 2,3-dioxygenases by cryoreduction EPR and ENDOR spectroscopy
J. Am. Chem. Soc.
132
5494-5500
2010
Homo sapiens, Shewanella oneidensis, Xanthomonas campestris
Manually annotated by BRENDA team
Tattevin, P.; Monnier, D.; Tribut, O.; Dulong, J.; Bescher, N.; Mourcin, F.; Uhel, F.; Le Tulzo, Y.; Tarte, K.
Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock
J. Infect. Dis.
201
956-966
2010
Homo sapiens
Manually annotated by BRENDA team
Roehrig, U.F.; Awad, L.; Grosdidier, A.; Larrieu, P.; Stroobant, V.; Colau, D.; Cerundolo, V.; Simpson, A.J.; Vogel, P.; Van den Eynde, B.J.; Zoete, V.; Michielin, O.
Rational design of indoleamine 2,3-dioxygenase inhibitors
J. Med. Chem.
53
1172-1189
2010
Homo sapiens (P14902)
Manually annotated by BRENDA team
Avril, T.; Saikali, S.; Vauleon, E.; Jary, A.; Hamlat, A.; De Tayrac, M.; Mosser, J.; Quillien, V.
Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions
J. Neuroimmunol.
225
22-33
2010
Homo sapiens
Manually annotated by BRENDA team
Samikkannu, T.; Rao, K.V.; Gandhi, N.; Saxena, S.K.; Nair, M.P.
Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS
J. NeuroVirol.
16
255-263
2010
Homo sapiens
Manually annotated by BRENDA team
Mao, R.; Zhang, J.; Jiang, D.; Cai, D.; Levy, J.M.; Cuconati, A.; Block, T.M.; Guo, J.T.; Guo, H.
Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells
J. Virol.
85
1048-1057
2011
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Mouratidis, P.X.; George, A.J.
Transfection of indoleamine 2,3 dioxygenase in primary endothelial cells
Methods Mol. Biol.
616
149-159
2010
Homo sapiens
Manually annotated by BRENDA team
Orabona, C.; Grohmann, U.
Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond
Methods Mol. Biol.
677
269-280
2011
Homo sapiens
Manually annotated by BRENDA team
Capece, L.; Arrar, M.; Roitberg, A.E.; Yeh, S.R.; Marti, M.A.; Estrin, D.A.
Substrate stereo-specificity in tryptophan dioxygenase and indoleamine 2,3-dioxygenase
Proteins
78
2961-2972
2010
Homo sapiens (P14902), Homo sapiens, Xanthomonas campestris (Q8PDA8)
Manually annotated by BRENDA team
Bonda, D.J.; Mailankot, M.; Stone, J.G.; Garrett, M.R.; Staniszewska, M.; Castellani, R.J.; Siedlak, S.L.; Zhu, X.; Lee, H.G.; Perry, G.; Nagaraj, R.H.; Smith, M.A.
Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimers disease
Redox Rep.
15
161-168
2010
Homo sapiens
Manually annotated by BRENDA team
Fatokun, A.A.; Hunt, N.H.; Ball, H.J.
Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease
Amino Acids
45
1319-1329
2013
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Capece, L.; Lewis-Ballester, A.; Marti, M.A.; Estrin, D.A.; Yeh, S.R.
Molecular basis for the substrate stereoselectivity in tryptophan dioxygenase
Biochemistry
50
10910-10918
2011
Homo sapiens, Xanthomonas campestris
Manually annotated by BRENDA team
Meininger, D.; Zalameda, L.; Liu, Y.; Stepan, L.P.; Borges, L.; McCarter, J.D.; Sutherland, C.L.
Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors
Biochim. Biophys. Acta
1814
1947-1954
2011
Homo sapiens (F5H5G0), Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Huang, Q.; Zheng, M.; Yang, S.; Kuang, C.; Yu, C.; Yang, Q.
Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors
Eur. J. Med. Chem.
46
5680-5687
2011
Homo sapiens
Manually annotated by BRENDA team
Eleftheriadis, T.; Pissas, G.; Karioti, A.; Antoniadi, G.; Liakopoulos, V.; Dafopoulou, K.; Pournaras, S.; Koukoulis, G.; Stefanidis, I.
The indoleamine 2,3-dioxygenase inhibitor 1-methyl-tryptophan suppresses mitochondrial function, induces aerobic glycolysis and decreases interleukin-10 production in human lymphocytes
Immunol. Invest.
41
507-520
2012
Homo sapiens
Manually annotated by BRENDA team
Freewan, M.; Rees, M.D.; Plaza, T.S.; Glaros, E.; Lim, Y.J.; Wang, X.S.; Yeung, A.W.; Witting, P.K.; Terentis, A.C.; Thomas, S.R.
Human indoleamine 2,3-dioxygenase is a catalyst of physiological heme peroxidase reactions: implications for the inhibition of dioxygenase activity by hydrogen peroxide
J. Biol. Chem.
288
1548-1567
2013
Homo sapiens
Manually annotated by BRENDA team
Wu, W.; Nicolazzo, J.A.; Wen, L.; Chung, R.; Stankovic, R.; Bao, S.S.; Lim, C.K.; Brew, B.J.; Cullen, K.M.; Guillemin, G.J.
Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimers disease brain
PLoS ONE
8
e59749
2013
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Kuo, H.H.; Mauk, A.G.
Indole peroxygenase activity of indoleamine 2,3-dioxygenase
Proc. Natl. Acad. Sci. USA
109
13966-13971
2012
Homo sapiens
Manually annotated by BRENDA team
Pantouris, G.; Serys, M.; Yuasa, H.J.; Ball, H.J.; Mowat, C.G.
Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1
Amino Acids
46
2155-2163
2014
Homo sapiens (P14902), Homo sapiens (Q6ZQW0), Homo sapiens
Manually annotated by BRENDA team
Kolawole, A.O.; Hixon, B.P.; Dameron, L.S.; Chrisman, I.M.; Smirnov, V.V.
Catalytic activity of human indoleamine 2,3-dioxygenase (hIDO1) at low oxygen
Arch. Biochem. Biophys.
570
47-57
2015
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Alvarez, L.; Lewis-Ballester, A.; Roitberg, A.; Estrin, D.A.; Yeh, S.R.; Marti, M.A.; Capece, L.
Structural study of a flexible active site loop in human indoleamine 2,3-dioxygenase and its functional implications
Biochemistry
55
2785-2793
2016
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Nienhaus, K.; Nickel, E.; Nienhaus, G.U.
Substrate binding in human indoleamine 2,3-dioxygenase 1 a spectroscopic analysis
Biochim. Biophys. Acta
1865
453-463
2017
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Cheng, M.F.; Hung, M.S.; Song, J.S.; Lin, S.Y.; Liao, F.Y.; Wu, M.H.; Hsiao, W.; Hsieh, C.L.; Wu, J.S.; Chao, Y.S.; Shih, C.; Wu, S.Y.; Ueng, S.H.
Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors
Bioorg. Med. Chem. Lett.
24
3403-3406
2014
Homo sapiens (P14902)
Manually annotated by BRENDA team
Tomek, P.; Palmer, B.D.; Flanagan, J.U.; Sun, C.; Raven, E.L.; Ching, L.M.
Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) probing the active site-inhibitor interactions
Eur. J. Med. Chem.
126
983-996
2017
Homo sapiens (P14902)
Manually annotated by BRENDA team
Eleftheriadis, T.; Pissas, G.; Antoniadi, G.; Liakopoulos, V.; Stefanidis, I.
Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells
Immunology
146
292-300
2015
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Eleftheriadis, T.; Pissas, G.; Sounidaki, M.; Tsogka, K.; Antoniadis, N.; Antoniadi, G.; Liakopoulos, V.; Stefanidis, I.
Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferaseI activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells
Int. J. Mol. Med.
38
1605-1613
2016
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Booth, E.S.; Basran, J.; Lee, M.; Handa, S.; Raven, E.L.
Substrate oxidation by indoleamine 2,3-dioxygenase evidence for a common reaction mechanism
J. Biol. Chem.
290
30924-30930
2015
Homo sapiens (P14902)
Manually annotated by BRENDA team
Yuasa, H.J.; Ball, H.J.
Efficient tryptophan-catabolizing activity is consistently conserved through evolution of TDO enzymes, but not IDO enzymes
J. Exp. Zool. B
324
128-140
2015
Strongylocentrotus purpuratus, Xenopus laevis (A2BD60), Nematostella vectensis (A7SDW8), Monosiga brevicollis (A9UVU0), Danio rerio (B0V1K8), Branchiostoma floridae (C3Y9Y8), Homo sapiens (P14902), Mus musculus (P28776), Mus musculus (Q8R0V5), Haliotis diversicolor (Q6F3I3)
Manually annotated by BRENDA team
Wu, J.S.; Lin, S.Y.; Liao, F.Y.; Hsiao, W.C.; Lee, L.C.; Peng, Y.H.; Hsieh, C.L.; Wu, M.H.; Song, J.S.; Yueh, A.; Chen, C.H.; Yeh, S.H.; Liu, C.Y.; Lin, S.Y.; Yeh, T.K.; Hsu, J.T.; Shih, C.; Ueng, S.H.; Hung, M.S.; Wu, S.Y.
Identification of substituted naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening
J. Med. Chem.
58
7807-7819
2015
Homo sapiens (P14902)
Manually annotated by BRENDA team
Li, R.; Li, H.; Sun, Q.; Liu, L.; Zhang, C.; Ren, X.
Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway
Mol. Immunol.
81
102-107
2017
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Gonzalez Esquivel, D.; Ramirez-Ortega, D.; Pineda, B.; Castro, N.; Rios, C.; Perez de la Cruz, V.
Kynurenine pathway metabolites and enzymes involved in redox reactions
Neuropharmacology
112
331-345
2017
Homo sapiens (P14902), Homo sapiens (Q6ZQW0), Mus musculus (P28776)
Manually annotated by BRENDA team
Yamamoto, R.; Yamamoto, Y.; Imai, S.; Fukutomi, R.; Ozawa, Y.; Abe, M.; Matuo, Y.; Saito, K.
Effects of various phytochemicals on indoleamine 2,3-dioxygenase 1 activity galanal is a novel, competitive inhibitor of the enzyme
PLoS ONE
9
e88789
2014
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Costabile, M.; Bassal, N.K.; Gerber, J.P.; Hughes, B.P.
Inhibition of indoleamine 2,3-dioxygenase activity by fatty acids and prostaglandins A structure function analysis
Prostaglandins Leukot. Essent. Fatty Acids
122
7-15
2017
Homo sapiens
Manually annotated by BRENDA team
Lin, S.Y.; Yeh, T.K.; Song, J.S.; Hung, M.S.; Cheng, M.F.; Liao, F.Y.; Li, A.S.; Cheng, S.Y.; Lin, L.M.; Chiu, C.H.; Wu, M.H.; Lin, Y.J.; Hsiao, W.; Sun, M.; Wang, Y.H.; Huang, C.H.; Tang, Y.C.; Chang, H.H.; Huang, Z.T.; Chao, Y.S.; Shih, C.; Pan, S.L.; Wu, S.Y.; Kuo, C.C.; Ueng, S.H.
4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy
Bioorg. Chem.
77
600-607
2018
Homo sapiens (P14902)
Manually annotated by BRENDA team
Balti, M.; Plas, A.; Meinguet, C.; Haufroid, M.; Themans, Q.; Efrit, M.L.; Wouters, J.; Lanners, S.
Synthesis of 4- and 5-arylthiazolinethiones as inhibitors of indoleamine 2,3-dioxygenase
Bioorg. Med. Chem. Lett.
27
3607-3610
2017
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Markwalder, J.A.; Seitz, S.P.; Blat, Y.; Elkin, L.; Hunt, J.T.; Pabalan, J.G.; Jure-Kunkel, M.N.; Vite, G.D.; Covello, K.
Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors
Bioorg. Med. Chem. Lett.
27
582-585
2017
Homo sapiens (P14902)
Manually annotated by BRENDA team
Griglio, A.; Torre, E.; Serafini, M.; Bianchi, A.; Schmid, R.; Coda Zabetta, G.; Massarotti, A.; Sorba, G.; Pirali, T.; Fallarini, S.
A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors Synthesis, biological investigation and docking studies
Bioorg. Med. Chem. Lett.
28
651-657
2018
Homo sapiens (P14902)
Manually annotated by BRENDA team
Williams, D.K.; Markwalder, J.A.; Balog, A.J.; Chen, B.; Chen, L.; Donnell, J.; Haque, L.; Hart, A.C.; Mandal, S.K.; Nation, A.; Shan, W.; Vite, G.D.; Covello, K.; Hunt, J.T.; Jure-Kunkel, M.N.; Seitz, S.P.
Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Bioorg. Med. Chem. Lett.
28
732-736
2018
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Kong, K.M.; Zhang, J.W.; Liu, B.Z.; Meng, G.R.; Zhang, Q.
Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Bioorg. Med. Chem. Lett.
30
126901
2020
Homo sapiens (P14902)
Manually annotated by BRENDA team
Li, Y.; Zhang, S.; Wang, R.; Cui, M.; Liu, W.; Yang, Q.; Kuang, C.
Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase
Bioorg. Med. Chem. Lett.
30
127159
2020
Homo sapiens (P14902)
Manually annotated by BRENDA team
Yanagisawa, S.; Kayama, K.; Hara, M.; Sugimoto, H.; Shiro, Y.; Ogura, T.
UV Resonance Raman characterization of a substrate bound to human indoleamine 2,3-dioxygenase 1
Biophys. J.
117
706-716
2019
Homo sapiens (P14902)
Manually annotated by BRENDA team
Klar, R.; Michel, S.; Schell, M.; Hinterwimmer, L.; Zippelius, A.; Jaschinski, F.
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression
Cancer Immunol. Immunother.
69
57-67
2020
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Xu, H.; Song, Y.; Yang, Q.
A novel high throughput virtual screening protocol to discover new indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Chem. Pharm. Bull.
65
714-717
2017
Homo sapiens (P14902)
Manually annotated by BRENDA team
Kwon, M.; Ko, S.K.; Jang, M.; Kim, G.H.; Ryoo, I.J.; Son, S.; Ryu, H.W.; Oh, S.R.; Lee, W.K.; Kim, B.Y.; Jang, J.H.; Ahn, J.S.
Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity
J. Enzyme Inhib. Med. Chem.
34
1481-1488
2019
Homo sapiens (P14902)
Manually annotated by BRENDA team
Roehrig, U.F.; Reynaud, A.; Majjigapu, S.R.; Vogel, P.; Pojer, F.; Zoete, V.
Inhibition mechanisms of indoleamine 2,3-dioxygenase 1 (IDO1)
J. Med. Chem.
62
8784-8795
2019
Homo sapiens (P14902)
Manually annotated by BRENDA team
Peng, Y.H.; Liao, F.Y.; Tseng, C.T.; Kuppusamy, R.; Li, A.S.; Chen, C.H.; Fan, Y.S.; Wang, S.Y.; Wu, M.H.; Hsueh, C.C.; Chang, J.Y.; Lee, L.C.; Shih, C.; Shia, K.S.; Yeh, T.K.; Hung, M.S.; Kuo, C.C.; Song, J.S.; Wu, S.Y.; Ueng, S.H.
Unique sulfur-aromatic interactions contribute to the binding of potent imidazothiazole indoleamine 2,3-dioxygenase inhibitors
J. Med. Chem.
63
1642-1659
2020
Homo sapiens (P14902)
Manually annotated by BRENDA team
Ning, X.L.; Li, Y.Z.; Huo, C.; Deng, J.; Gao, C.; Zhu, K.R.; Wang, M.; Wu, Y.X.; Yu, J.L.; Ren, Y.L.; Luo, Z.Y.; Li, G.; Chen, Y.; Wang, S.Y.; Peng, C.; Yang, L.L.; Wang, Z.Y.; Wu, Y.; Qian, S.; Li, G.B.
X-ray structure-guided discovery of a potent, orally bioavailable, dual human indoleamine/tryptophan 2,3-dioxygenase (hIDO/hTDO) inhibitor that shows activity in a mouse model of Parkinsons disease
J. Med. Chem.
64
8303-8332
2021
Homo sapiens (P14902), Homo sapiens
Manually annotated by BRENDA team
Bando, H.; Lee, Y.; Sakaguchi, N.; Pradipta, A.; Ma, J.S.; Tanaka, S.; Cai, Y.; Liu, J.; Shen, J.; Nishikawa, Y.; Sasai, M.; Yamamoto, M.
Inducible nitric oxide synthase is a key host factor for Toxoplasma GRA15-dependent disruption of the gamma interferon-induced antiparasitic human response
mBio
9
e01738-18
2018
Homo sapiens (P14902)
Manually annotated by BRENDA team
Zhao, H.; Sun, P.; Guo, W.; Wang, Y.; Zhang, A.; Meng, L.; Ding, C.
Discovery of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitors based on ortho-naphthaquinone-containing natural product
Molecules
24
1059
2019
Homo sapiens (P14902)
Manually annotated by BRENDA team
Sari, S.; Tomek, P.; Leung, E.; Reynisson, J.
Discovery and characterisation of dual inhibitors of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1) using virtual screening
Molecules
24
4346
2019
Homo sapiens (P14902)
Manually annotated by BRENDA team
Dolsak, A.; Gobec, S.; Sova, M.
Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets
Pharmacol. Ther.
221
107746
2021
Homo sapiens (P14902), Homo sapiens (Q6ZQW0)
Manually annotated by BRENDA team